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1. Introduction 
Bovine mastitis is a disease that affects dairy herd production, characterized by considerable 
economical loss due to diminished milk secretion, potential productive cow damage, 
increase in production costs and milk contamination. Intramammary infection (IMMI) is the 
most common reason for the use of antimicrobials in dairy cows. Antimicrobials (ATMs) 
have been used to treat mastitis for more than fifty years, but consensus about the most 
efficient, safe, and economical treatment is still lacking.  
Staphylococcus aureus is considered one of the main bacteria causing bovine mastitis, which is 
widely distributed in different countries. S. aureus is Gram-positive cocci, catalase-positive 
and facultative anaerobe. The Staphylococcus genus comprises more than thirty species 
which are able to colonize many environments and are part of the cutaneous or mucousal 
flora of various animals and humans. The intracellular survival of S. aureus is believed to 
contribute to the recurrence of some infections such as mastitis. Some publications reported 
the ability of this pathogen to colonize multiple cell types. However the precise fate of 
intracellular S. aureus is still poorly understood.  
The general lack of therapeutic success against subclinical mastitis caused by S. aureus has 
prompted a reevaluation of treatment strategies. Despite the availability of several 
antibiotics with good in vitro activity, cure rates are poor, suggesting that inadequate 
concentrations of active antibiotic are coming into contact with the infecting bacteria for 
sufficient time and /or adequate concentrations to be effective.  
Over the last few years, much concern has been raised regarding the optimization of 
antibiotic use, owing to the worrying increase of bacterial resistance. In this context, 
progress in the field of anti-infective pharmacology has led to the emergence of a new 
discipline, referred to as pharmacokinetics/pharmacodynamics (PK/PD) of antibiotics,  the 
discipline that strives to understand the relationships between drug concentrations and 
effects, both desirable (bacterial killing) and undesirable (bacterial resistance). Over the past 
15 years, three key PK/PD parameters have been elaborated, which determine how 
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antibiotic concentrations reached in body fluids over time (as predicted from the PK profile 
of the drug) compare with potentially effective antibiotic concentrations (as deduced from 
the minimal inhibitory concentration (MIC) or minimal bactericidal concentration (MBC) of 
antibiotics in vitro). The first parameter is the time during which concentrations of the ATM 
are above the MIC (t > MIC), it links bactericidal effects to time and is critically dependent 
on the half-life of the drug, dosage and frequency of administration over a given period of 
time. The second parameter is the peak plasma concentration divided by the MIC 
(Cmax/MIC), it relates bactericidal effects to concentration, and is primarily dependent on 
the dose. The third parameter is the area under the concentration-time curve divided by the 
MIC (AUC/MIC), and it combines both types of effects, since it corresponds to the total 
amount of drug to which bacteria are exposed over the time period, and is directly related to 
the total dose given during that period and inversely proportional to the drug clearance 
(Van Bambeke et al., 2006).  
These parameters are critical in predicting antibiotic activity and, therefore, in establishing 
dosages on a rational basis. The application of these parameters, however, have  so far been 
limited to extracellular infections in well-vascularized tissues, because they are all based on 
serum antibiotic levels.  
Antimicrobials exhibit three major patterns of ATM activity. The first pattern in 
characterized by concentration dependent killing and moderate to prolonged persistent 
effects. Higher concentrations would kill organisms more rapidly and more extensively than 
lower levels. The prolonged persistent effects would allow for the administration of large 
doses with long inter-dose periods. Microorganism regrowth is not immediate at the time in 
which the drug concentrations fall below the MIC. This called post antibiotic effect is 
variable between different drug types but always present for ATMs exhibiting this kind of 
killing. This pattern is observed with aminoglycosides, fluoroquinolones, daptomycin, 
ketolides, and amphotericin B. The goal of a dosing regimen for these drugs would be to 
maximize concentrations. The peak level and the AUC should be the pharmacokinetic 
parameters that would determine in vivo efficacy (Andes et al., 2001; Craig, 2001).  
The second pattern is characterized by time-dependent killing and minimal to moderate 
persistent effects. High drug levels would not kill organisms better than lower 
concentrations. Furthermore, organism regrowth would start very soon after serum levels 
fall below the MIC. This pattern is observed with β-lactams, macrolides, clindamycin, and 
oxazolidinones. The goal of a dose regime for these drugs would be to optimize the duration 
of exposure. The duration of time that serum levels exceed some minimal value such as the 
MIC should be the major parameter determining the in vivo efficacy of these drugs (Andes 
et al., 2001; Craig, 2001).  
The third pattern is also characterized by time-dependent killing, but the duration of the 
persistent effects is much prolonged. This can prevent any regrowth during the dosing 
interval. This pattern is observed with azithromycin, tetracyclines, quinupristin-dalfopristin, 
glycopeptides, and fluconazole. The goal of a dose regime is to optimize the amount of drug 
administered to ensure that killing occurs for part of the time and there is no regrowth 
during the dosing interval. The AUC should be the primary pharmacokinetic parameter that 
would determine in vivo efficacy (Andes et al., 2001; Craig, 2001). 
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Antimicrobial PK/PD relationship reflects a correlation between the drug concentrations in 
the blood, the concentration of the biologically active drug at the site of the infection, and 
the microbial or clinical outcome (Levison, 2004). The PK component describes the 
processing of the drug by the host (absorption, distribution, metabolism, and elimination). 
The PD component describes the effect of the drug on the bacterial pathogen. By identifying 
an association between PK and PD for specific host-drug-microbe combinations, the PK/PD 
approach provides a valuable guide for estimating the doses and dosage regimens that can 
optimize the bacteriological or clinical outcome. 
The extent to which a drug has access into milk when given systemically, or is absorbed and 
distributes throughout the udder when given intramammarily, depends on its properties: 
lipid solubility, degree of ionization, and extent of binding to serum and udder proteins. 
High lipid solubility, poor degree of ionization and less plasma protein binding contributes 
to a better transfer into milk. With IMM preparations, the type of vehicle is also important.  
Weak organic bases like macrolides and sulfonamidestend to accumulate in milk in the 
ionized form after parenteral administration, and attain concentrations higher than those in 
blood. On the other hand, concentrations of weak acids like penicillins and cephalosporins 
in milk are significantly lower than those in blood. In the concentration-dependent group of 
ATMs (e.g. aminoglycosides and fluoroquinolones) concentration of several times the MIC 
for the target organisms at the infection site increases the efficacy. In the time dependent 
group (e.g. penicillins, cephalosporins and classical macrolides) the efficacy depends on the 
time during which the concentration of the drug exceeds the MIC, but high concentrations 
do not increase efficacy.  
While there are a number of factors that contribute to the PK/PD indexes (e.g. in vitro MIC 
of the drug, its post-antibiotic effects –PAE-, and sub-MIC effects), there are also several 
factors that the traditional PK/PD approach does not describe. For example, the in vitro 
MIC, which is the basis for the PD component of these indices, does not provide information 
on time to kill, time to maximum kill, log change within a fixed time, or the maximum 
reduction in viable bacterial counts. There are also many others in vivo factors that influence 
ATM effectiveness (e.g. anti-inflammatory effects, presence of bacterial biofilms, the drug´s 
ability to interfere with bacterial colonization on epithelial surface, and influence of the drug 
on toxin production and release). Furthermore, plasma drug concentrations do not 
necessarily reflect a compound´s ability to diffuse into the site of infection and into the 
bacterial cell. 
An ideal drug for mastitis therapy should have a low MIC for mastitis pathogens. As 
treatment should be efficient and targeted towards specific infections, Gram-negative and 
Gram-positive infections in fact would require different ATMs. Antimastitic drugs should 
preferably have bactericidal action, as phagocites act normally immediately after milking, 
but as time elapses they incorporates fat globules becoming “engorged” thus diminishing its 
phagocytic capacity. As a consequence milk phagocytes are less effective than plasma ones. 
Milk should not interfere with ATM activity.  
The objective of this study was to make a bibliographic compilation on the PK of different 
ATM agents in milk, based in our experience and some other relevant publications, and to 
establish the relationship between the PK and the PD interaction with the target bacteria. 
We consider that non prudent use of ATMs in dairy farms can be fought through the 
implementation of rational therapeutical procedures based on the following items: 
www.intechopen.com
 
A Bird's-Eye View of Veterinary Medicine 
 
426 
1. Knowledge on the microbiological profile of mastitis. Clinical and laboratory diagnosis 
(isolation, typification and antibiogram) is one of the basic pillars for the rational use of 
ATM agents. 
2. Knowledge on the PK and PD of antibiotics in milk producing animals, both healthy 
and mastitic. Understanding the relation PK/PD in these animals will result in an 
increase of ATM efficiency and a decrease in the selection of resistant strains, two 
important aspects leading to the success of the therapy. 
3. More efficient and safer prescription of antimastitic drugs. The development of new 
products should involve more than just the discovery of a new substance; it should deal 
with the full utilization of the effects of the agents in the organism. The way a drug is 
transported to the target location should be considered; once there, it should be 
available in the appropriate concentration and time to be effective. 
4. Establishment of the correct withdrawal periods for the antibiotics tested, following 
internationally agreed protocols. 
2. General pharmacokinetic considerations 
An important question regarding the treatment of mastitis is whether the ATM should 
accumulate in milk or in the udder tissue (Erskine et al., 2003). The target site may depend 
on the causative agent: streptococci are known to remain in the milk compartment, but S. 
aureus penetrates udder tissue and causes deep infection (Table 1). The most common route 
of administration of ATMs in mastitis is the IMM route. Efficacy of IMM treatment varies 
according to the pathogen, with the best therapeutic response being shown for mastitis 
caused by streptococci, coagulase-negative staphylococci, and Corynebacterium spp. 
 Milk/ducts Udder tissue Cow 
Streptococcus agalactiae +++ --- --- 
Other streptococci +++ + --- 
Staphylococcus aureus + +++ --- 
Coagulase-negative staphylococci +++ --- --- 
Arcanobacterium pyogenes (summer mastitis) --- ++ +++ 
Coliforms + -- +++ 
Table 1. Where to target ATM therapy in clinical mastitis due to different pathogens 
(Erskine et al., 2003) 
2.1 Parenteral antimicrobial treatments  
Systemic administration for treatment of mastitis was first used in the 70's (Ziv, 1980a). In 
acute cases, the IMM administration often fails due to poor and uneven distribution of the 
drug, either by the growth of breast parenchyma or blockage caused by the products of 
inflammation. In these circumstances, parenteral therapy is preferred (Mestorino, 1993a). 
From the clinical point of view, the success of parenteral therapy depends mainly on the 
ATM passage from blood to milk (Ziv, 1980a). The ATM concentrations in highly 
vascularized tissues are equivalent to those determined in blood plasma. By contrast, in 
places where the irrigation is poor or those which are separated from the central 
compartment by biological membranes, drug levels are not equivalent (Baggot, 1986). The 
time during which concentrations in the mammary gland are effective depends largely on 
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the drug characteristics, the dose, the bioavailability of the molecule, the ability to penetrate 
the mammary gland and the microorganism susceptibility (Ziv, 1980b; Mestorino, 1993a). 
The ability to penetrate the mammary gland or milk bioavailability (Fmilk) is determined by 
the ratio AUC0-∞ milk / AUC0-∞ plasma, as shown in the following equation: 
 
0 ( )
0 ( )
milk
milk
serum
AUC
F
AUC


  (1) 
This equation determines the relationship between the amount of ATM that is absorbed to 
the central compartment and the amount of ATM that passes through the mammary gland 
for reaches the milk compartment (Mestorino, 1993a). 
Those antibiotics that have a high volume of distribution penetrate better into the mammary 
gland. However, differences in the degree of penetration blood: milk occur even among 
compounds that are chemically and structurally related. These differences can be explained 
by the principle of passive diffusion (Ziv, 1980b). ATMs cross biological membranes by 
passive diffusion or specialized transport.  
Since the surface of the lipid portion of the membrane is extremely high, passive diffusion 
through membranes can be considered synonymous of diffusion through membrane lipids 
(Errecalde, 2004). The transfer in this case is directly proportional to the concentration 
gradient and the lipid-to-water partition coefficient of the ATM (Ziv, 1980b). 
Weak organic acids and bases are found in milk and plasma as ionized or nonionized forms. 
The nonionized fraction is generally more soluble than the ionized one and diffuses better 
through the biological membrane (Ziv, 1980b; Errecalde, 2004; Mestorino, 1993a). The 
proportion of the drug in the nonionized form depends on the pKa of the molecule and the 
pH of the medium in which it is dissolved. When the molecules pass through the membrane 
by simple diffusion, are distributed according to their degree of ionization, the charge of 
their ionized form and the extent of protein binding. This is because the molecules bound to 
proteins or tissues are not able to cross membranes (Ziv, 1980b). 
The theoretical relationship between the drug concentrations on both sides of a biological 
membrane can be calculated according to the Jacobs equation, that for organic acids such as 
penicillin G (pKa = 2.8) is the following: 
 Ratio milk:plasma = 1 10
1 10
milk a
plasma a
pH pK
pH pK



  (2) 
And in the case of organic bases, such as spiramycin (pKa = 8.2) is: 
 Ratio milk:plasma= 1 10
1 10
a milk
a plasma
pK pH
pK pH
 
   (3) 
The serum pH is 7.4 and the milk has a pH between 6.6 – 6.8. The organic bases 
administered by the parenteral route tends to accumulate in milk and remain there in its 
ionized form (ion trapping), thus achieving milk concentrations which exceed those in 
plasma. Instead, the concentrations of weak acids in milk are lower than those found in 
plasma (Erskine, 2002b). 
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That is to say that the majority of the drugs can be ionized or nonionized according to its 
pKa and the pH of the surrounding environment. Nonionized compounds have a higher 
lipid-water partition coefficient than the ionized ones and thus it is easier for them to diffuse 
through lipidic membranes. The amphoteric molecules, such as danofloxacin (pKa = 6.2 to 
9.4) does not depend on the relationship pK/pH and therefore its distribution is essentially 
determined by the degree of lipid solubility of the molecule and consequently by its lipid-
water partition coefficient. 
Table 2 shows different ATMs with its theoretical and experimental milk: plasma ratios. 
Observing this table we can conclude that the diffusion of organic acids into milk is highly 
predictable, but the diffusion of organic bases can be predicted only when these are largely 
nonionized in plasma and have a moderate degree of lipid solubility. 
Antimicrobial agent
Chemical 
nature 
PKa 
Lipid 
solubility 
Milk to serum concentration 
ratio Theoretical - Experimental 
Sulfanilamide Acid 10.4 Moderate 1.00 – 0.97 
Sulfathiazole Acid 7.1 Moderate 0.37 – 0.35 
Sulfadiazine Acid 6.5 Moderate 0.28 – 0.21 
Penicillin G Acid 2.8 Moderate 0.16 – 0.20 
Cloxacillin Acid 2.8 High 0.16 – 0.22 
Ampicillin Acid 
2.8; 
7.2 
High 0.26 – 0.26 
Amoxicillin Acid 
2.8; 
7.2 
High 0.26 – 0.26 
Cephacetrile Acid 2.4 Moderate 0.12 – 0.15 
Cephapirin Acid 2.6 Moderate 0.14 – 0.18 
Rifamycin SV Acid 
2.8; 
6.7 
Moderate 0.25 – 0.25 
Rifampicin Acid 7.9 High 0.85 – 1.10 
Novobiocin Acid 4.3 High 0.30 – 0.,33 
Penethamate Base 8.5 High 5.7 – 6.1 
Streptomycin, 
neomycin 
Base 8.9 Low 7.5 – 0.5 
Polymyxin B, colistin Base 10.0 Very low 8.0 – 0.3 
Erythromycin Base 8.8 High 6.5 – 8.5 
Tylosin Base 7.1 High 5.0 – 4.5 
Spiramycin Base 8.2 High 4.8 – 4.6 
Lincomycin, 
clindamycin 
Base 7.6 High 4.2 – 4.4 
Tetracyclines Amphoteric - Moderate 0.4; 0.8 – 0.6; 1.4 
Table 2. Partition of ATMs in plasma and milk in lactating animals. From Ziv G. (1980b) 
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In the case of a weak base, when administered parenterally, e.g intramuscularly, the rapid 
penetration from blood to milk is characterized by early appearance of measurable 
concentrations in this fluid, a ratio Cmax (plasma) /Cmax (milk) less than or equal to 1, a t-lag 
between the Cmax (plasma) and Cmax (milk) short and a ratio AUC (plasma) /AUC (milk) less than or 
equal to 1 (Ziv, 1980b).  
During the mastitis process, the chemical composition of milk presents changes consequence 
of the inflammatory process. There are ions, proteins and inflammatory cells passage from 
blood into the gland lumen, because of a great increase in the vascular permeability. The 
physical properties of milk are also affected and there is an increase of pH, conductivity and 
viscosity, while the density and redox potential decrease (Korhonen & Kaartinen, 1995). 
In mastitic milk it is expected that the passage of organic bases is diminished as the pH 
increases in detriment to the ion trapping in milk. However, the lipid solubility of this kind 
of molecules suggests that the relationship milk:plasma is always greater than 1 (Ziv, 1980b). 
In the case of organic acids, the penetration is favored by the increase of milk pH. However, 
these compounds will reach milk: plasma ratios above 1 only when the milk pH exceeds 7.4. 
This indicates that lipophilic weak bases parenterally administered may have a certain 
advantage in distribution into milk in comparison with acids (Ziv, 1980b). 
2.2 Intramammary antimicrobial treatments (IMM) 
The IMM infusion is the more used administration route in the ATM treatment of mastitis. 
However, many IMM products have been released to the market without the necessary 
scientific support about its PK behavior and studies about its clinical and bacteriological 
efficacy. The benefits of IMM administration are the high concentrations reached in milk 
and less loss due to drug absorption and transfer processes through biological membranes. 
While the disadvantages of this route may be the uneven distribution of various compounds 
within the udder, the risk of mammary contamination by bacteria inoculation through the 
teat canal and the possible irritation of tissue breast by the formulation  (Gruet et al., 2001). 
Even in vitro studies have shown that ATMs administered by IMM route can negatively 
affect the phagocytic process in the mammary environment (Nickerson et al., 1985; 1986). 
After administration of an IMM infusion, the contact between the ATM agent and the 
pathogen within the mammary gland is subject to a series of successive events (Ziv, 1980c; 
Mestorino, 1993a): 
1. Pharmaceutical Phase: begins after drug administration including the following steps: 
 Disintegration of the formulation 
 Drug dissolution 
 Liberation of the drug in milk 
2. Pharmacokinetic Phase: Assumes the presence of the drug in milk (drug availability) 
and includes the following events: 
 Absorption (milk: plasma) 
 Distribution (local and systemic) 
 Metabolism (systemic) 
 Excretion (local and systemic) 
3. Pharmacodynamic Phase: The effect of the drug against bacteria in the infection site. 
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The kind and proportions of the pharmaceutical excipients contained in the formulation are 
which determines the rate of drug release. They define the pharmaceutic phase which 
governs the initial shape of the ATM milk concentration versus time curve.  
IMM formulations used for mastitis treatment during lactation contain pharmaceutical 
excipients that favors quick release of the active components, because the objective is to 
eradicate the infection of glandular tissue and minimize the withdrawal time (Ziv, 1980c).  
On the other hand, when the IMM treatment is during the dry period, the process of release 
of the active component must be slow and necessarily has great influence on the initial 
shape of the concentration versus time curve. The excipients used, although very variable,   
may include vegetable or mineral oils. The mineral oil, such as paraffin or glycerine oils, has 
the advantage of delaying the release of the active compound and prolonge the permanence 
of the ATM inside the gland (Ziv, 1980c; Mattie et al., 1997). 
In some cases the pharmaceutical excipients contain other agents that increase the retention, 
such as aluminum monostearate in an oily base, hydroxystearin (Ziv, 1980c). Mercer et al. 
(1974) studied the absorption in blood and the persistence in milk of penicillin G, after IMM 
infusion of 400000 IU in mastitic quarters in a rapid (aqueous formulation) and a slow 
release base (3.6% aluminum monostearate in peanut oil). Penicillin G administered in the 
slow release formulation could still be detected in the milk 120 h after infusion compared to 
only 56 h for the aqueous base formulation. These figures must be considered in relation to 
the MIC of penicillin G for S. aureus in milk which is around 0.1 IU.mL-1; this means that 
active levels were maintained above the MIC for 72 h for the oil-based formulation 
compared to 32 h for the aqueous-based formulation. After the administration of IMM 
syringes, part of the formulation will be lost with the milk in the first milking post-
treatment. This loss is negligible in the case of treatment at the start of the dry period, 
because the cows are removed from the milking routine. However, the disruptions of the 
milking routine trigger physiological changes in the mammary gland that may affect the 
pharmaceutical and PK phases. 
The start of the PK phase presupposes the existence of available drug in the milk secretion 
and depends on the disintegration of the formulation and the dissolution of the drug. These 
processes determine the drug availability. 
The amount of drug recovered in milk is influenced by several factors, among which we can 
mention the kind of excipient used in the formulation, the milk: plasma passage rate, the 
size of the udder and the volume of milk contained in the gland (Ziv, 1980c). 
The passage of the antibiotic from milk to serum involves the movement of drug across a 
biological membrane. The factors influencing this passage are the same that affect their 
transfer from the blood into the milk: the molecule pKa, the lipid solubility of the 
nonionized fraction, the percentage of udder tissue binding and the binding to milk proteins 
(Mestorino, 1993a). Hydro soluble drugs pass through the membrane mainly through the 
protein channels. Lipid soluble drugs cross the membrane through the lipoproteic region .  
The ability to cross the milk: plasma barrier is expressed as lipid solubility coefficient for 
nonionized fraction percentage (Mattie et al., 1997) and the real rate of passage can be 
quantified by the Cmax(plasma)/Cmax (milk) or by the AUC(plasma) / AUC(milk) ratios (Ziv, 1980a). 
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The milk: plasma absorption phenomenon results in the presence of the ATM agent in blood 
plasma. Once in the systemic circulation, the drug will be object of the PKs phenomena 
taking place after absorption (distribution, metabolism and excretion) (Ziv, 1980b). 
The ATM distribution inside the gland occurs by passive diffusion of the molecules through 
the lipophilic and hydrophilic components of the glandular secretion. This phenomenon is 
affected by drug binding to breast tissue and / or components of milk (Mestorino, 1993a). 
Once the drug establishes contact with the glandular cells, its penetration into tissue 
continues depending on lipophilicity. As will be detailed later, cell penetration is a critical 
point in certain infections. The excretion process of the ATM from the mammary gland is 
governed by the kind of excipient used, the quantity of milk produced, the molecule 
characteristics, the health of the mammary gland, the number of daily milkings made (Ziv, 
1980c), the dose and total volume of formulation among  other factors. 
After the IMM treatment at cow drying, the ATMs elimination from the mammary gland 
can be expressed by a monoexponential or biexponential curve. The elimination rate is 
affected by the dose, the nature of the vehicle, the drug characteristics, and the extent of 
binding of the antibacterial agent to the gland content and to the mammary tissue (Ziv, 
1980c; Mestorino, 1993a; Mattie et al., 1997). 
3. Antimicrobial pharmacodynamic concepts 
Successful ATM chemotherapy depends on a correct diagnosis, selection of the appropriate 
ATM agent, and its administration with an adequate dosing scheme. 
When considering the choice of ATM agent and dosage regimen, we need to consider the 
PKs of the chosen drug in the target animal species and the PD indices that drive its clinical 
effectiveness. For example, penicillins, like all β-lactam ATMs (penicillins, cephalosporins, 
carbapenems and monobactams), exhibit time-dependent killing. This means that maximum 
clinical effectiveness is achieved by ensuring that the free serum concentration of the 
selected β-lactam exceeds the MIC of the pathogen for the appropriate percentage of the 
dosing interval. If the pathogen is a Gram-positive organism, the targeted duration is 
usually ≥40% of the dosing interval. Instead, concentrations of most β-lactams should 
exceed the MIC of the pathogen by ≥80% of the dosing interval when the infectious agent is 
a Gram-negative organism. In other words, for drugs exhibiting time-dependent killing, 
increasing the concentration of the drug in excess of the MIC of the pathogen does not 
increase the killing rate. Rather, the extent of killing is dictated by the duration of time that 
bacteria are exposed to the drug. 
On the other hand, other bactericidal ATM agents, as fluoroquinolones and 
aminoglycosides, exhibit concentration-dependent killing. In this situation, the rate of 
killing increases as the drug concentration increases above the MIC of the bacterial 
pathogen. Thus, ATM agents may be classified as those that exhibit time-dependent killing 
with null or brief post-antibiotic effect (e.g. β-lactams), time-dependent killing with 
prolonged post-antibiotic effect (e.g. glycopeptides), concentration dependent killing (e.g. 
fluorquinolones and aminoglycosides), and those that are generally considered to be 
bacteriostatic (e.g. tetracyclines, macrolides, lincosamides and phenicols). 
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Mouton et al. (2005) published an attempt to standardize the interpretation n of these 
various PK/PD parameters (Fig. 1). Some of the basic definitions are as follow: 
 AUC (area under the concentration versus time curve). Should be expressed in terms of 
unbound drug. If multiple dosing regimens are applied, AUC should be measured over 
a 24 hour dosing interval at steady state. It should be noted that for compounds 
exhibiting linear PK, the AUC over a single dosing interval at steady state (AUC0-τ) is 
equal to AUC extrapolated to infinity (AUC0-∞) following single administration. 
 AUC/MIC (AUC divided the minimum inhibitory concentration). Although sometimes 
given the dimension of time (generally 18 to 24 hours), this ratio can be more 
conveniently expressed as a dimensionless value. 
 T>MIC (period of time during which the drug concentrations exceed the MIC). The 
cumulative percentage of a 24-hour period that the free drug concentration exceeds the 
MIC at steady-state pharmacokinetic conditions. 
 In vitro PAE (post-antibiotic effect). The period of suppression of bacterial growth after 
short exposure of an organism to an ATM compound (unit = time). 
 In vivo PAE. The difference in time for the number of bacteria in a tissue of treated 
versus control animals to increase 1 log10 over values when drug concentration in 
serum or at the infection site fall below the MIC (unit = time). The in vivo PAE includes 
any effect associated with sub-MIC concentrations. Sub MIC effect. Any effect of an 
ATM on a microorganism at concentrations below the MIC (unit = time) 
 Post-antibiotic sub-MIC effect. The effect of sub-MIC drug concentrations on bacterial 
growth following serial exposure to drug concentrations exceeding the MIC (unit = 
time) 
 
Fig. 1. Illustration of the main PK/PD parameters that correlate with efficacy against 
extracellular infections. 
The units associated with the AUC/MIC ratio are hours, by dividing this value by the 
dosing interval (e.g. 24 hour), we obtain the average plasma concentration over the steady-
state 24-hour dosing interval relative to MIC, which may be far more informative than the 
traditional method for expressing this value. 
The PD parameter providing the most appropriate surrogate for drug effectiveness is 
dependent on several factors. This includes: mechanism of action of the different drugs, 
whether its effects are time or concentration dependent, and the PAE duration (Table 3). 
www.intechopen.com
 
Pharmacokinetic-Pharmacodynamic Considerations for Bovine Mastitis Treatment 
 
433 
Drug Mechanism Activity 
Bacterial 
effect 
Duration PAE 
PD 
Parameter 
Macrolides 
Erythromycin, 
Binds to 50S 
ribosomes (inhibits 
proteins synthesis)
Static 
Time-
dependent 
Brief* T>MIC 
Azalides 
Azithromycin 
 
“ 
  
 
Prolonged 
 
AUC24/MIC 
Lincosamides “   Brief AUC24/MIC 
Ketolides 
(telithromycin) 
Binds to 50S 
ribosomes and 
some 30S ribosomal 
unit activity 
Static and cidal 
(S.pneumoniae, 
S.pyogenes) 
Time-
dependent 
Prolonged AUC24/MIC 
Β-lactams(e.g. 
penicillins, 
cephalosporins, 
carbapenems, 
monobactams) 
Inhibits cell wall 
synthesis 
Cidal 
Time-
dependent 
Gram- bacteria: 
null or brief, 
Gram+: may be 
prolonged 
T>MIC 
Glycopeptides 
(e.g.vancomycin) 
Inhibits cell wall 
synthesis 
Cidal(slower than 
β-lactams) 
Time-
dependent 
Prolonged AUC24/MIC 
fluoroquinolone 
(e.g. 
enrofloxacin, 
ciprofloxacin, 
danofloxacin) 
Inhibit DNA gyrase, 
prents transcription 
and replication 
Cidal 
Concentration
-dependent 
Prolonged 
AUC24/MIC 
Cmax/MIC 
Aminoglycosides 
(e.g.gentamycin, 
streptomycin) 
Binds to 30S 
ribosome (inhibits 
protein synthesis) 
and disrupts 
biofilms 
Cidal 
Concentration
-dependent 
Prolonged 
AUC24/MIC 
Cmax/MIC 
Tetracyclines 
Inhibits protein 
synthesis (30S) 
Static 
Time-
dependent 
Prolonged AUC24/MIC 
Phenicols 
(e.g.chloramphen
icol, florfenicol, 
thiamphenicol) 
Inhibits protein 
synthesis by 
inhibition peptydyl-
transferase (50S) 
Static 
Time-
dependent 
Prolonged AUC24/MIC 
Trimethoprim 
Inhibits folic acid 
synthesis by 
inhibiting 
dihydrofolate 
reductase 
Static alone 
Cidal with 
sulfonamides 
Time-
dependent 
Brief T>MIC 
Sulfonamides 
PABA analogue 
interferes with folic 
acid synthesis 
Static 
Time-
dependent 
Brief T>MIC 
Oxazolidinones 
(linezolid) 
Inhibits initiation of 
protein synthesis 
(50S) 
Static (Staph. and 
Enterococcus) 
Cidal (most 
Strep.) 
Time-
dependent 
Brief T>MIC 
Table 3. Relationships among drug, drug effects, and the PD surrogate most closely aligned 
to its clinical response (Martinez et al, 2006). *Brief: less than one hour. Prolonged: up to six 
hours. 
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Whether a drug exhibits concentration-dependent or time-dependent killing is largely a 
function of the shape of its concentration-effect curve, the steeper the curve, the less will be 
the impact of increasing drug concentrations on the ATM response. Conversely, the more 
shallows the curve, the greater the relationships between the rates of bacterial kill versus the 
ATM drug concentration. This relationship can be described using a sigmoidal Emax model, 
also known as the Hill model, which can be described as follows (Toutain, 2002): 
 0
50
max ( )
( )
( )
h
h h
E C t
E t E
EC C t
   (4) 
Where: 
E(t) is the effect observed for a given concentration at time t  (C (t)) ; 
Emax is the maximal effect attributable to the drug; 
EC50 is the plasma concentration producing 50% of Emax ; 
h is the Hill coefficient, which adjust the degree of sigmoidicity in the curve; and 
E0 describes the rate of spontaneous cure. 
When  h= 1, the Hill model reduces to the Emax model, which corresponds to a hyperbolic 
function.  
While there are certain characteristics common to all ATMs within a given drug class, there 
can be important differences in the PK/PD ratios needed to achieve a desired effect. Within 
the fluoroquinolones (FQ), it has been demonstrated that the rate of kill and the duration of 
the in vitro PAE (Finberg et al., 2004; Firsov et al., 1998b) can be markedly different across 
compounds and microbial species. In some cases, the PK/PD relationship necessary to 
achieve a 2-log kill can also vary as a function of the microbial strain (Andes and Craig, 
2002). Similarly, the AUC/MIC ratio of 100-125 frequently quoted as a target for FQ ATM 
activity may be an appropriate predictor of success for many Gram-negative infections, but  
lower AUC/MIC ratios (e.g. 35 to 40) may be appropriate for infections due to Gram 
positive organisms (Wright et al., 2000). With regard to the β-lactams, while there tends to 
be a substantial in vivo PAE for S. aureus, a substantially shorter PAE is associated with 
Gram negative organisms (Craig, 1993). 
Within any given bacterial population, the possibilities of bacterial subpopulations that are 
less susceptible to the ATM agent exist. As demonstrated by Drusano (2004), unless these 
less susceptible pathogens are killed, succeeding microbial generations will re-populate the 
infection site with pathogens whose MIC values are higher than those found within the 
initial infection.  
Accordingly, ensuring adequate exposure following an initial dose of a FQ is as important 
as insuring that high drug concentrations occur after repeated administration. Drug 
concentrations need to be adequate to either destroy the existing bacterial population at the 
site of the infection or to reduce its size to the point where the host defense mechanism can 
successfully control and eliminate the remaining pathogens. 
For drugs exhibiting concentration-dependent killing, Cmax/MIC ratios may be particularly 
important when the pathogen has a high MIC value or is rapidly proliferating (Craig and 
Dalhoff, 1998). Rapidly proliferating bacteria have a greater likelihood of undergoing a 
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mutational event that could lead to the genesis of a less susceptible population. In infectious 
disease processes where there is a high bacterial burden (inoculum effect), the risk of a 
mutational event is increased due simply to the laws of probability (Craig and Dalhoff, 
1998). In these cases, to ensure maximum killing, the targeted Cmax/MIC ratios are 
approximately 10 to 12 (Drusano et al., 1993). Such ratios ensure increased killing of 
susceptible organisms and an increased killing or inhibition of organisms with higher MICs. 
The goal in these situations is to reduce bacterial numbers to a level where the host can 
effectively handle those pathogens not killed by the ATM agent. While a high Cmax/MIC 
ratio (e.g. 10) is correlated with a high rate of bacterial kill for compounds exhibiting 
concentration-dependent killing, there are conditions under which AUC/MIC may be as or 
more predictive of a sustained ATM activity. AUC/MIC could be considered a major 
PK/PD parameter when the infection is caused by relatively slow growing bacteria, when 
there is little or no PAE that will contribute to inhibition of bacterial re-growth or when the 
MIC for the pathogen is relatively low. 
3.1 Post-Antibiotic Effects (PAE) 
High drug concentrations relative to the MIC may contribute to an increase in the duration 
of the in vitro and in vivo PAE. For those bacteria/drug combinations that exhibit a PAE, in 
vivo PAEs have been shown to be longer than in vitro PAEs for most organisms. Thus, 
optimizing the Cmax/MIC ratio will delay the re-growth of the pathogen, sometimes by 
several hours. This type of dosing schemes results in fewer organisms remaining that can 
evolve into a resistant subpopulation and can be managed by the host defenses. 
For many compounds, the duration of the in vivo and in vitro PAE is substantially greater 
for Gram-positive than for Gram-negative pathogens. Because the duration of the in vitro 
and in vivo PAE of β-lactams tends to be negligible for Gram-negative species, it is 
recommended that concentrations of drug remain above the MIC of the pathogen for >80% 
of the dosing interval to combat this type of organisms. While a T>MIC of about 40% is 
sufficient for staphylococcal species. 
This difference in the duration of the in vitro and in vivo PAE may also be one of the reasons 
why the in vivo AUC/MIC for FQ tends to be less for Gram-positive than for Gram-
negative pathogens. For Gram-negative organisms, the estimated AUC/MIC ratios needed 
to ensure effective treatment and prevent the selection of resistant strains is estimated to be 
approximately 100 to 125 (Forrest et al., 1993). In contrast, the AUC/MIC ratio for Gram-
positive bacteria is considerably lower, approximately 30 to 50 for a number of drug-
pathogen combinations (Wright et al., 2000). Studies involving the third and fourth 
generation FQ suggest that for Gram-positive organisms AUC/MIC values are substantially 
lower when Cmax/MIC values are ≥10 (Nightingale et al., 2000). 
Blood concentrations and MIC data alone cannot predict drug effectiveness. For example, 
using human and bovine estimated breakpoints for cephapirin and oxytetracycline, 
Constable and Morin (2002) showed that the MIC values predicted that the causative 
pathogens would be susceptible to both agents. However, these compounds were not 
effective in the treatment of acute bovine mastitis. In the same line, compounds effective in 
the treatment of acute bovine mastitis may be ineffective in the treatment of chronic bovine 
mastitis (Owens et al., 1997). 
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Drug potency is often considered in terms of MIC, which is a measure of a drug´s static 
effect on microbial growth. The MIC may not be the same as a compound´s minimum 
bactericidal concentration (MBC). Since both the MIC and MBC values are in vitro estimates, 
they do not reflect the killing rate of a drug, the effect of serum on ATM activity, PAE, or 
post-ATM sub-MIC (Craig and Dalhoff, 1998). Firsov et al. (1999) demonstrated that even 
with comparable AUC/MIC ratios, different FQ can have marked differences in in-vitro 
time-kill profiles. Such differences cannot only influence the selection of an AUC/MIC 
target value, but also the potential for selecting for resistant bacterial strains. 
Traditional in vitro susceptibility data reflect the impact of therapeutic agents on bacteria 
that are in the active growth phase. These tests do not describe the differential activity 
across the different life phases of bacteria (Cerca et al., 2005). As an example, in the case of 
bacteria from biofilms, entering a non-growth phase, many compounds begin to lose their 
ATM effects. This very important facts cannot be predicted when MIC alone is used as the 
PD component of the PK/PD relationship.  
There are some examples of traditional susceptibility tests failing to adequately reflect in vivo 
drug activity. For instance, β-lactams are inactivated by purulent material due to the 
accumulation of bacterial β-lactamases; gentamicin can be inactivated by reversibly binding to 
DNA released from lysed neutrophils; netilmicin and amikacin are inactivated by disrupted 
leukocytes (Labro, 2000). Owens et al. (1997) noted that the bacteriologic cure rate for newly 
(less than two weeks duration) acquired S. aureus IMMI, was 70% when treated with penicillin 
and novobiocin combination. However, the cure rate dropped to less than 35% for chronic 
infections (those lasting longer than four weeks). Accordingly, they observed that while the 
successful treatment of acute infections could be predicted on the basis of in vitro susceptibility 
test results, this was not the case for chronic S. aureus infections. It is not know if this outcome 
is due to the driving of S. aureus infections from extracellular to intracellular sites, to biofilm 
formation, or to some other bacterial pathogen-host interaction (Brouillete et al., 2004). 
Staphylococcal bovine mastitis exemplifies a persistent infection that is difficult to treat and 
where frequent relapses commonly lead to a chronic disease (Sandholm et al., 1990). 
Antibiotic treatment of this disease is problematic (as mentioned in the preceding 
paragraphs) partly because in vitro antibacterial susceptibility is a poor predictor of efficacy 
in chronic cows (Owens et al., 1997). Failure to eliminate the infection from dairy herds is 
likely due to a combination of an adaptive response of the pathogen to survive in the 
mammary gland despite the presence of antibiotics (Sandholm et al., 1990), and the inability 
of host defenses to clear the pathogen. Infectious bacteria in chronic mastitis may survive 
intracellularly and remain quiescent and protected from the action of antibacterials and host 
defenses. Although reinfections that follow attempts to treat acute mastitis can be due to 
newly acquired strains, it is equally possible that the reinfection results from persistence of 
the original infective organism (Sandholm et al., 1990). It is possible that S. aureus having the 
small-colony variants (SCV) phenotype contribute to chronic mastitis. SCVs have been 
isolated from cases of bovine mastitis (Ziv & Sompolinsky, 1976; Sompolinsky et al., 1969). 
Both lactational and dry cow therapy are part of S. aureus control programs. Reported cure 
rates for S. aureus mastitis vary considerably in a range from 4 to 92% (Owens et al., 1988, 
1997). The probability of cure depends on cow, pathogen, and treatment factors. Cure rates 
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decrease with increasing age of the cow, increasing somatic cell count, increasing duration 
of infection, increasing bacterial colony counts in milk before treatment, and increasing 
number of quarters infected. S. aureus mastitis in hind quarters has a low cure rate 
compared with front quarters. ATM treatment of IMMI with penicillin-resistant S. aureus 
strains results in a lower cure rate for treatment with either β-lactam or non-β-lactam 
antibiotics. The most important treatment factor affecting cure is treatment duration. 
Increased duration of treatment is associated with increased chance of cure. Economically, 
extended treatment is not always justified, even when indirect effects of treatment such as 
prevention of contagious transmission are taken into consideration.  
The β-lactams (penicillins and cephalosporins) have become the first line of ATM agents 
used for treatment of bovine mastitis in Argentina. Within this class, penicillin, amoxicillin, 
cloxacillin and ampicillin are the most used agents. In the Nordic countries penicillin is used 
as the first-line antibiotic treatment of bovine mastitis, because of its potency, low resistance 
rate and narrow spectrum. This is an important tool to limit the development of antibiotic 
resistance as much as possible. In a one study performed for us 34% of S. aureus were 
classified as penicillin resistant, while 100% were classified as sensible to the combination 
amoxicillin/clavulanic acid (Lucas, 2009a). This prevalence of resistance to penicillin was 
similar than those obtained by others authors in different regions of Argentina (Gentilini et 
al., 2000; Russi et al., 2008). And this was the same comparing the proportion of resistance 
(47 %) as obtained by Gianneechini et al. (2002) in Uruguay. The comparison between these 
results obtained over the years demonstrated that the situation in general has not changed 
during the last 25 years in relation to penicillin resistance. However, it results higher than in 
Norway, 4.2% from clinical cases and 18% from sub-clinical cases (Hofshager et al., 1999), 
and Sweden, 6% (Franklin, 1998). In the Table 4 we present in vitro susceptibility results of 
strains of S. aureus obtained by different studies performed in different countries.  
4. Specific antimicrobial agents 
4.1 Beta-lactam agents 
4.1.1 Amoxicillin 
The use of β-lactam antibiotics in the treatment of mastitis remains one of the first elections. 
Within this group, any penicillin (PEN) such as amoxicillin (AMX) provides a number of 
advantages. AMX is a β-lactam antibiotic of wide spectrum with a chemical structure and 
antibacterial activity similar to ampicillin (AMP) (Hunter et al., 1973).  
AMX is rapidly converted to AMP in the body. AMX pharmacokinetics is essentially similar to 
other β-lactam antibiotics. The half-life is short (about 1 hour) and the volume of distribution 
low. The first AMX pharmacokinetic study was conducted in ruminants after IV and IM 
administration in cattle and after IM administration in goats by Ziv and Nouws (1979).  
Since then AMX disposition was studied after its administration by different routes in 
production animals (Archimbault et al, 1981; Baggot, 1988, Nouws et al, 1986, Wilson et al, 
1988). According to Erskine et al. (2002) about 60% of S. aureus isolates are susceptible to 
AMP. The susceptibility to AMP among mastitis causing streptococci is 100% and for E.coli 
85%. Therefore, significant improvement by AMX/clavulanic acid treatment compared to 
AMX or AMP alone can be expected only for S. aureus. 
www.intechopen.com
 
A Bird's-Eye View of Veterinary Medicine 
 
438 
 MIC (µg.mL-1)  
Antimicrobial 
agent MIC50 MIC90 Range 
Resistance 
Breakpoint 
References 
Penicillin 
0.5 
0.06 
0.25 
0.06 
>8 
0.5 
1 
4 
0.12 - > 8
0.06-0.5 
0.062-2 
0.03-8 
≥0.25 
Gianneechini et al., 2002 
Rubin et al., 2011 
San Martín et al., 2002 
Russi et al., 2008 
Ampicillin 
0.5
0.125
8
1
≤0.12->16 
0.06-4
≥0.5 Gianneechini et al., 2002 
San Martín et al., 2002 
Amoxicillin 0.125 1 0.06-4 ≥0.5 San Martín et al., 2002 
AMX/CLA 2 2 2 – 16 ≥8 Rubin et al., 2011 
Oxacillin  
Cloxacillin 
 
≤0.5 
0.25 
0.25 
≤0.5 
2 
1 
≤0.5-1 
0.12-0.5 
0.125-16 
≥4 
Gianneechini et al., 2002; 
Russi et al., 2008 
Lucas, 2009 
San Martín et al., 2002 
Cephalotin ≤4 ≤4 4-64 ≥32 Gianneechini et al., 2002; 
Rubin et al., 2011 
Cephoperaz. 0.5 2 0.25-16 ≥8 San Martín et al., 2002 
Gentamicin 
≤1
2 
1 
0.25 
≤1
2 
4 
0.5 
≤1-4
2-16 
0.25-32 
0.03-2 
≥16 
Gianneechini et al., 2002;  
Rubin et al., 2011  
San Martín et al., 2002 
Russi et al., 2008 
Neomycin ≤1 ≤1 ≤1-64 ≥64 Gianneechini et al., 2002 
Oxitetracy-
cline 
2
2 
2
>64
2 
4
≤0.25->64 
2-32 
0.5-64
≥16 
Gianneechini et al., 2002 
Rubin et al., 2011 
San Martín et al., 2002 
Erythromycin 
≤0.5
0.25 
0.125 
≤0.5
0.25 
0.25 
≤0.5->4
0.25-16 
0.125-0.5
≥8 
Gianneechini et al., 2002 
Rubin et al., 2011 
Russi et al., 2008 
Azythromycin 0.5 1 0.25-2 Lucas, 2009
Spiramycin 4 4 0.5-4 Lucas, 2009
Clindamycin 
≤1 
0.25 
≤1 
0.25 
≤1 
0.25-16 
≥4 Gianneechini (2002) 
Rubin et al., 2011 
Chloramph. 4 8 4-32 ≥32 Rubin et al., 2011 
Florfenicol 0.5 2 0.25-128 ≥32 San Martín et al., 2002 
Enrofloxacin 
≤0.25
≤0.25 
0.125 
≤0.25
≤0.25 
0.5 
≤0.25-0.5
0.25-16 
0.06-8 
≥4 
Gianneechini (2002) 
Rubin et al., 2011 
San Martín et al., 2002 
Danofloxacin 0.25 1 0.25-2  Lucas, 2009 
Trimethoprim/ 
Sulfamethox 
0.25 
19 
0.5 
19 
<0.006-8 
19-76 
≥4 
76 
Gianneechini (2002) 
Rubin et al., 2011 
Table 4. In vitro susceptibility of strains of S. aureus obtained from clinical and sub-clinical 
bovine mastitis cases by different authors. 
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We performed some studies with the objective of evaluating the PK behavior of AMX 
trihydrate in serum and milk after its IM administration at therapeutic dose in healthy 
lactating cows (Mestorino et al., 1997) (Fig. 2). AMX was absorbed relatively fast after its 
administration (T ½ab 0.92 ± 0.10 h). Because AMX trihydrate was used, and that this is not a 
water soluble salt, the formulation to be administered was a suspension. This formulation 
allows a fraction of the AMX dose to be rapidly liberated and absorbed whereas another 
fraction, less soluble, is precipitated at the site of administration, and absorbed more slowly, 
leading to the slow elimination profile described, which allows the estimation of dosing 
regimens with long intervals. It should be emphasized that the profile of long-acting 
medication is not due to slow elimination, but a slow absorption. The drug is eliminated at 
normal speed, but no molecules are available at a higher rate of absorption; therefore it is 
the absorption process that commands the elimination half-life. 
 
Fig. 2. AMX concentrations in serum and milk after IM administration of 15 mg.kg-1 to four 
healthy dairy cows. 
The average time of penetration into milk (T ½P) of 1.24 ± 0.09 h, was considered fast enough 
for an antimastitic agent. The ratio AUCmilk: AUCserum was 0.18, which is a low level of milk 
availability (Table 5). Beta-lactam antibiotics, due to their acidic character are more 
dissociated in plasma than in milk, so milk penetration is severely restricted. Serum and 
milk concentrations were determined until 48 h post-administration, which, considering the 
mentioned MIC90 of S. aureus, does not represent a good therapeutic tool because Cmax in 
milk was only 0.44 ± 0.13 µg.mL-1. It has to be remarked that the mentioned parameter was 
obtained in healthy animals. In mastitic animals, on the other hand, it appears logical to 
expect a greater penetration of AMX in the gland, because raising the pH, would permit 
greater dissociation of AMX in the cistern, and a process of ion sequestration with higher 
drug concentrations in milk. In view of the influence of the factors mentioned above, PK 
studies should always be performed not only on healthy animals but on sick animals too. 
The most significant factor affecting the cure rates for clinical S. aureus mastitis is the ability 
of the isolate to produce ß-lactamase. This has also been shown by other authors (Sol et al. 
2000), and could indicate either that penicillin resistant strains are more virulent than 
penicillin-susceptible strains, or that the antibiotics used to treat mastitis caused by 
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penicillin-resistant strains are less efficient, due to PK or PD factors, as we explained above. 
In the study by Sol et al. (2000), clinical S. aureus mastitis caused by ß-lactamase positive or 
negative isolates was treated intramammarily with 5 different ATM treatments. All the 
isolates were found to be in vitro susceptible to the drugs used. 
Parameter Serum Milk 
Kabs (h-1) 0.75 ± 0.09 0.56 ± 0.08
T ½ abs (h) 0.92 ± 0.10 1.24 ± 0.09
Cmax (µg.ml-1) 1.29 ± 0.14 0.44 ± 0.13
Tmax (h) 2.00 ± 0.00 4.00 ± 0.00
ß (h-1)  0.025± 0.07 0.03 ± 0.001
T½ ß (h)  27.61± 0.09 22.59± 0.91
AUC (µg.h/ml) 57.72± 3.87 10.34± 1.28
R CmaxS/CmaxM   2.93 
R AUCM/AUCS   0.18 
FMilk (%)  18 
Table 5. PK parameters (mean ± SD, N = 4) obtained in serum and milk after IM 
administration of AMX at dose of 15mg.kg-1 in dairy cows  
No difference in the bacteriological cure rates between the different ATM treatments in each 
group was found, but  major differences in bacteriological cure rates between mastitis due to 
ß-lactamase positive and negative strains was significant. S. aureus is known to possess 
many virulence factors, like capsule and slime formation, which make it more resistant to 
ATMs (Sandholm et al. 1990; Taponen et al., 2003). 
Information about the PKs of systemic amoxicillin-clavulanic acid (AMX-CLA) suspension 
in dairy cows is almost totally lacking. However AMX-CLA is widespreadly used in 
veterinary medicine. Injectable formulations (IM) have been used in cattle, pigs and sheep, 
and oral formulations for the treatment of pre-ruminant animals. Like other β-lactams, AMX 
alone or combined with CLA is commercially available for IMM use in bovine mastitis. 
There are few antecedents of combining an IMM treatment with a systemic one, and, in 
general these studies compare clinical efficacy without PK determinations (Ziv 1980a; 
1980c). As this is an interesting strategy to treat mastitis, we decided to compare the 
pharmacokinetic behaviour of AMX-CLA after their IMM infusion vs the combination 
therapy IMM-IM in lactating Holstein cows with subclinical mastitis caused by S. aureus 
(Lucas et al., 2009a). The experimental animals were allocated by production level (high and 
low production level)  and the quarters were grouped by health state. In the IMM alone 
assay, each quarter of all cows received 3 IMM infusions of AMX-CLA (200-50 mg) with a 12 
h interval. Individual quarter milk samples were collected until 96 h after 3rd administration 
(Fig 3). The purpose was to evaluate the effects of the health status of the quarters (SS): 
mastitic quarters vs. healthy ones and the level of milk production (LP): quarters of high-
producing cows vs quarters of low-producing cows. LP had a significant effect on T½β and 
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MRT, which were higher in quarters of low producing-cows (P<0.05). The MIC90 for AMX-
CLA 4:1 was 8 µg.mL-1 and the T>MIC90 was higher in quarters of low-producing cows. The 
LP modified the AMX-CLA PK profile and it could be a determinant of efficacy. 
It resulted remarkable that levels of AMX were higher and remained for a longer period of 
time in the mammary quarters of low production cows than in the quarters of high 
production cows. These differences were not such in the case of CLA, as calculated 
parameters were similar in both groups. We determined also the T>MIC90 in the milk of 
each quarter (MIC90= 6.4:1.6 µg.ml-1) (See Table 6). The health status of the mammary 
quarters had no statistically significant effect on any of the PK parameters. The level of milk 
production, however, had a significant effect on the AMX T½ǌ (P= 0.0000), AUC0-∞ (P = 
0.0057), CL/F (P=0.0057) and MRT (P= 0.0019). 
IMM treatment given to supplement systemic administration of ATMs increases drug 
concentration in the milk compartment, and higher concentrations throughout the 
mammary gland will follow (Ziv 1980a; 1980c). In theory, combination treatment thus 
should improve cure rates for deep infections such as S. aureus mastitis (Sandholm et al. 
1990). On the other hand, ß-lactam ATMs are time-dependent drugs, and very high 
concentrations at the infection site do not increase efficacy (Craig 2001).  
 
Fig. 3. Mean concentrations of AMX-CLA in milk of healthy and mastitic quarters after 
administration of 3 IMM syringes (200 mg-50 mg) every 12 h  
 X mastitic ± SD X healthy ± SD XM high prod. ± SD XM low prod. ± SD 
T>MIC90 (%) 52.78 ± 30.71 48.60 ± 31.65 46.30 ± 35.80 53.69 ± 26.72 
Table 6. T>MIC90 (%): percentage of the period between 0 and 12 h post-administration 
during which the concentration was ≥ the MIC90; Amx:Cla 4:1, the MIC90 was considered as 
the ratio 4:1 (MIC90= 6.4:1.6 µg.mL-1) 
We performed another study where the effect of the combined IMM treatment with systemic 
administration was evaluated (Lucas et al., 2009a). The experimental animals received 3 IMM 
infusions of AMX-CLA (200-50 mg) in each quarter in combination with 3.5 mg.kg-1 of 15% 
AMX-CLA by IM route every 12 h. Individual quarter milk samples were collected until 96 h 
after 3rd administration. The incidence of the health status of the quarters (SS): mastitic 
quarters vs. healthy ones, and the level of milk production (LP): quarters of high-producing 
cows vs quarters of low-producing cows in the PKs of the drugs was evaluated (Fig. 4). 
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We determined once again the T>MIC90 in the milk of each quarter (MIC90= 6.4:1.6 µg.ml-1) 
(See Table 7). It was observed that concentrations achieved in cows receiving combination 
therapy (IM + IMM) were higher than those in cows treated intramammarly alone, which 
was a logical finding. 
 
Fig. 4. Mean concentrations of AMX-CLA in milk of healthy and mastitic quarters after 
administration of 3 IMM syringes (200 mg-50 mg each) in combination with three 3.5 mg.kg-
1 of 15% AMX-CLA  IM administrations  every 12 h  
Significant effects of quarter health status on the PK parameters were found. The Cmax 
resulted higher in milk from sick quarters (P= 0.0384). The level of production had 
significant effect over milk AMX Cmax and Tmax, these were higher in the mammary 
quarters of low production cows. The level of production also affected the PK profile of 
CLA, the Cmax, Tmax and AUC0-∞ were higher in animals of low production. The 
differences observed between CL/Fmam suggest that the ATMs removal rate was higher in 
the quarters of high production cows. Significant effect of the mammary quarter health 
status and production level on the T>MIC90 was found. It should be emphasized that the 
T>MIC determined after the combined treatment (IM + IMM) exceeded those calculated 
after IMM infusion alone. 
 Xmastitic ± SD Xhealthy ± SD XM high prod. ± SD XM low prod. ± SD 
T>MIC90 (%) 62.64 ± 8.87 78.25 ± 23.16 65.31 ± 20.33 79.48 ± 18.67 
Table 7. T>MIC90 (%): percentage of the period between 0 and 12 h post-administration 
during which the concentration was ≥ the MIC90; Amx:Cla 4:1, the MIC90 was considered as 
the ratio 4:1 (MIC90= 6.4:1.6 µg.mL-1) 
Owens et al. (1988) found higher cure rates in S. aureus mastitis with combined treatment as 
compared with IMM treatment only. Recently, the therapeutical effects of parenteral, IMM 
and combination treatments with AMX-CLA have been compared by Perner et al. 2002 too. 
They found the combination treatment to be superior than parenteral or IMM treatment 
only. In this paper, the bacteriological cure rate for all causing agents and mastitis types 
(acute, subclinical and chronic), was 75.3%. We found also low bacteriological cure rates 
(62.5%) after AMX-CLA IMM infusion alone, but after the combined treatment the cure rate 
was complete (100%) (Lucas et al., 2009a, b). 
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4.1.2 Penethamate 
Penethamate hydriodide (PNTM) is a diethylaminoethyl ester of penicillin which, unlike 
salts of penicillin, is unionised and so exists in a neutral state. It is only weakly water soluble 
forming a suspension in an aqueous environment. After its intramuscular administration, is 
rapidly absorbed from the site of injection and on entering the blood, partially dissociates by 
hydrolysis into penicillin G and diethylaminoethanol. At the blood pH (7.4), equilibrium is 
established where 90% of the active drug is present in its hydrolyzed form (penicillin G) 
with the remainder persisting as PNTM. As PNTM leaves the circulation due to its neutral 
and lipophilic properties and its high affinity to milk, this equilibrium is maintained by re-
association of penicillin G and diethylaminoethanol until excretion is complete. PNTM 
easily passes the milk-blood barrier due to the pH gradient between milk (pH 6.6-6.8) and 
plasma (pH 7.2-7.4) and its weakly basic properties (pKa = 8.4). This is further facilitated by 
its highly lipophylic characteristics which facilitates its passage across the lipo-proteic 
blood-milk barrier. PNTM starts to dissociate as it passes over the barrier and this process 
continues during diffusion of the drug through the udder, releasing increasing quantities of 
penicillin G (PENG). PENG is rapidly ionised in the udder (pKa = 2.8) so limiting its return to 
the circulation. It therefore becomes "trapped" in the udder in increasing concentrations. 
The same pH gradient between blood and milk presides in the case of mild to moderate 
udder inflammation such as in sub-clinical mastitis, the pH gradient between blood and 
milk is the same than in healthy animals thus generating similar PK behaviors to those 
which take place in the healthy udder. In acute mastitis, although the pH of milk is nearer 
that of blood due to a breakdown of the blood-milk barrier, higher concentrations of PNTM 
are still  found in mastitic milk than in blood due to its lipophilic properties. Not only does 
undissociated PNTM rapidly and easily penetrate the udder whether inflammed or not, but 
its liposoluble nature gives it advantage, compared with other beta-lactam antibiotics such 
as amoxicillin and aminoglycosides  to diffuse through the parenchyma of the udder, pass 
into the milk and penetrate the lactogenic cells. This diffusion through the udder is 
supported by the mechanism of "ion trapping" mentioned above and so explains the 
different penetration of PNTM compared with PENG (Friton et al., 2003). 
It must be remembered, however, that S. aureus survives in acidic media, including 
phagolysosomes. Controversial in vitro/in vivo data exist on its susceptibility to antibiotics 
in such environments. We performed some studies to evaluate the effect of the pH variation 
on the antibacterial activity of penicillin against strains of S. aureus isolated from mastitic 
quarters (Moncada Cárdenas et al., 2009). MIC of S. aureus field strains and S. aureus ATCC 
25923 were tested at pH 7.4, 6.5 and 5.0, in order to simulate the conditions of acidity of 
subcellular structures which are commonly associated with S. aureus intracellular 
persistence. The PEN MIC90 at pH 7.4 was consistent with those reported by CLSI 2007 (0.5 
Ǎg/mL) but at pH 5.0 (phagolysosomes) the activity of PENG increased markedly and 
almost linearly (~10 fold decrease in MIC -0.06 Ǎg/mL) (Figure 5).  
4.1.3 Cloxacillin 
Cloxacillin (CLX) is used in the treatment or prevention of staphylococcal bovine mastitis. 
Its ATM activity against S.aureus is higher than that of PENG. There are strains of S. aureus 
resistant to isoxazolilpenicillins (oxacillin or methicillin resistant S. aureus –MRSA). These 
strains are a menace to public health. 
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Fig. 5. Inhibition of S. aureus exposed to different concentrations (expressed as Log10) of PEN 
(0.25 MIC; 0.5MIC; 1MIC; 2MIC; 4MIC and 8 x MIC) in function of the time and the medium 
pH (5; 6.5 and 7.4). 
Benzathine CLX is used to treat bovine mastitis by IMM route at drying off and may be 
associated to other compounds, eg antiinflammatory agents (prednisolone) or other ATMs 
(eg. AMX, AMP, streptomycin, cephalosporins, etc.). Intramammary products with 
combinations of two or even three ATMs were introduced due to suggested synergistic 
action and broad spectrum. The evidence of their efficacy against clinical mastitis is many 
times lacking and synergistic action has never been proven in vivo (Taponen et al. 2003; 
Ødegaard & Sviland, 2001). For mastitis treatment during lactation the formulations contain 
CLX as sodium salt and, in general, the drug is not combined with other compounds. After 
IMM administration, sodium CLX binds scarcely to the mammary tissue (25%), with a 
moderate passage milk:plasma.  
We evaluated the pharmacokinetic behavior of sodium CLX in milk after its IMM 
administration in healthy lactating cows of low production. The experimental cows received 
syringes containing 250 mg sodium CLX IMM, three times at 12 hour intervals in each 
quarter. Milk samples were obtained at different post administration times (Fig. 6). 
The PK analysis was performed after the last administration. Milk elimination half-life was 
rather prolonged (T½β = 4.37 ± 0.458 h), with levels in milk at 60 h post-last administration 
≥0.35 µg.mL-1. In low production animals the elimination of the ATM is even slower, with 
longer milk half life (Table 8). Various benzathine CLX containing IMM suspensions are 
registered for use in cattle as antibiotics for IMM use at drying off. These formulations are 
recommended for routine use in cows at drying off to treat existing IMM infections and to 
provide prolonged protection against new infections during the next lactation.  
The excretion through the mammary gland depends on the characteristics of the 
pharmaceutical excipient, production level (high vs. low), molecule characteristic and udder 
health status (Mestorino, 1993a). The elimination rate is affected also by the binding level to 
dry udder secretion, which is very high (80%) ( Ødegaard & Sviland, 2001). 
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In a recent study, we obtained an MIC90 of 2 Ǎg.mL-1 against S.aureus (isolated from cattle 
with subclinical mastitis) (Lucas et al., 2009a).  
 
Fig. 6. Mean CLX concentrations in milk of dairy cows after IMM infusion of 250 mg CLX 
three times at 12 hour intervals in each mammary quarter.  
PARAMETER MEAN SD 
B (µg.mL-1) 1288.557 464.800 
ß (h-1) 0.160 0.016 
T 1/2ß  (hs) 4.370 0.458 
AUC0-all  (µg.h/ml) 7372.005 2062.654 
MTR (hs) 6.982 1.469 
Table 8. Mean pharmacokinetic parameters obtained in milk after IMM infusion of 250 mg 
CLX in each quarter three times at 12 hour intervals. 
An experiment was conducted in cows with staphylococcal subclinical mastitis  at drying off 
for the purpose of studying the pharmacokinetics behaviour of CLX benzathine in the dry 
udder secretion after a single IMM infusion (Lucas et al., 2009b) (Fig. 7). 
In Table 9 the CLX PK parameters in udder dry secretion are presented. We determined the 
T>MIC90 in the mammary dry secretion of each quarter. Normally, T>MIC90 is expressed as 
the percentage of time of the inter-dose interval during which the concentration remains 
above the MIC. Since we used a single dose of benzathine CLX in a slow-release 
formulation, there was no inter-dose interval. Therefore, with the objective of evaluating the 
PK behaviour based on the MIC, we estimated T>MIC90 as hours post-treatment during 
which the ATM concentration was above the MIC.  
The milk:plasma passage rate was very low and the CLX concentrations in plasma could not 
be measured. For mastitis treatment by IMM route it is desirable the permanence of the 
ATM in the mammary compartment or glandular tissue for a long time. 
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Therefore, these findings are acceptable considering that the formulation used is indicated for 
the IMM treatment of mastitis at drying off. The level of binding of CLX to dry udder secretion 
is high (86 ± 6.5 %), acting as a reservoir and increasing the persistence of the ATM inside the 
udder. The experimental animals maintained concentrations above the limit of quantitation by 
microbiological methods (0.03µg.mL-1) during the first 24-31 days. Oliver et al. (1990) found 
that after IMM administration of CLX at drying off, the secretion samples had detectable levels 
until 28-35 days post-treatment in some animals and until 42-49 in others. This finding shows a 
marked variability in CLX concentrations at drying off. The determinants of this variability are 
varied and complex:  udder size,  seasonal effects, body condition of cows, physiological changes 
in body condition at the start of  the dry period and other factors affecting gland and body. 
 
Fig. 7. Average CLX milk concentrations in dry udder secretion (mastitic vs. healthy) after 
the administration of one IMM syringe in each quarter at drying off (600 mg) 
Parameter Unit Mean mastitic ± SD Mean healthy ± SD 
T½λ h 48.13 ± 51.27 39.53 ± 27.29 
ABC0-24h µg.h.mL-1 2130.24 ± 797.31 2144.09 ± 850.06 
ABC0-∞ µg.h.mL-1 5003.07 ± 3292.88 5358.52 ± 3398.00
TMR h 62.98 ± 47.49 57.42 ± 35.07 
T>CIM90  257.14 ± 188.45 231.54 ± 153.82 
Table 9. CLX PKs in dry udder secretion  in mastitic quarters vs. healthy quarters after its  
administration at dose of 600 mg in each quarter at drying off. T>CIM90: post-administration 
hours during which CLX concentrations remained above the  MIC90 (2 Ǎg.mL-1) 
4.1.4 Cephalosporins 
Several IMM products for the IMM treatment of dairy cattle contain cephalosporins, most 
commonly as a single product (e.g., cefquinome; cephapirin), but also in combination 
(cephalexin and kanamycin). The cephalosporins are semisynthetic antibiotics derived from 
cephalosporin C (produced by Cephalosporium acremonium). There are currently 4 
generations of cephalosporins, which vary from the narrow-spectrum first generation 
through the expanded-spectrum fourth generation (Hornish and Kotarski, 2002), with all 
generations being used in veterinary medicinal products. When using a first-generation 
cephalosporin in an IMM preparation, there is a strong rationale for combining it with an 
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additional antibiotic to extend the spectrum of the product. There are cephalosporins that, 
when administered systemically penetrates in significantly low levels to the mammary 
gland of the producing cow. Is the case of ceftiofur. Ceftiofur is an interesting tool because it 
can be used in cows that are producing milk to treat infections that are located out of the 
mammary gland (metritis, foot infections), without discarding milk.  
4.2 Phenicols 
The toxicity of chloramphenicol (CAP) has been the cause of its use being banned or strictly 
regulated worldwide. This has accentuated the need for an effective broad-spectrum 
antibiotic to be used in food producing animals. Florfenicol (FLF) is a synthetic fluorinated 
CAP analogue that is exclusively used in food animals for treatment of infectious diseases. 
PK studies showed that high concentrations, both in serum and milk, are obtained following 
IMM administration in cows, which led to propose its use for the treatment of bovine 
mastitis. The FLF MIC90 among S. aureus obtained by San Martin was 2 Ǎg.mL-1 (2002). We 
obtained a thianphenicol (TAP) MIC90 higher than FLF (>16 µg.mL-1) (Lucas, 2009b).  
TAP is a structural analogue of CAP with marked toxicological differences (Mestorino et al., 
1993b). TAP has a greater in vitro activity against some bacteria that are resistant to CAP. 
Although TAP has similarities in its antibacterial spectrum with that of CAP, there are 
marked pharmacological differences between the two drugs. TAP is more stable in solution, 
is not appreciably protein bound in the body (16%) and does not undergo significant 
biotransformation. The drug diffuses into intracellular spaces, the central nervous system 
and the aqueous humour (Mestorino et al., 1993a; b). We performed a complete study about 
the TAP PK behavior in lactating healthy Holstein cows after its administration by 
intravenous, intramuscular, subcutaneous routes (Fig. 8) and after IMM infusion in a  
unique quarter and in the complete gland (in the four quarters) (Mestorino et al., 1993a; 
1993b; 1995). Serum PK after IV administration was described following a bicompartmental 
model. The antibiotic showed a rapid distribution, with a half life of 8.84 ± 4.34 min. Half life 
of elimination was 1.95 ± 0.55 h, indicating that TAP is rapidly eliminated in the bovine. 
Volume of distribution was high, 1404.18 ± 428.19 ml.kg-1. Milk concentrations were high, 
when the drug was administered systemically, with a mean time of gland penetration (T½P) 
rather fast of 36.58 ± 9.72 min and a half life of elimination from the gland of 3.62 ± 0.97 h, 
indicating that accumulation of TAP takes place in the mammary gland. A milk permanency 
time of 4.13 ± 1.13 days was determined (Table 10).  
A monocompartmental model was used to describe the PKs of TAP after its IM and SC 
administration. After IM administration, TAP was rapidly absorbed, with a half life of 6.53 ± 
6.25 min and a half life of elimination of 2.9 ± 0.50 h. Maximum concentration was 29.38 ± 
6.90 µg.mL-1 and was found at 0.32 ± 0.09 h. Area under the curve was 68.45 ± 16.27 
µg.h/mL and bioavailability 86.33 ± 19.08%. Milk therapeutic levels were maintained 
between 0.5 and 8 h with a Cmax of 17.05 ± 2.73 µg.mL-1 reached at 3.42 ± 0.19 h. Mammary 
gland half life of penetration was 51.11 ± 6.10 min and half life of elimination 5.31 ± 4.27 h. 
Ratio CmaxS:CmaxM was 1.81 and the ratio AUCM:AUCS 1.19. Theoretical milk permanency 
time was 4.79 ± 1.40 days. 
After SC administration a maximum serum concentration of 19.83 ± 3.57 µg.mL-1 was 
obtained at 0.72 ± 0.12 h with a half life of absorption of 10.09 ± 5.37 min. Half life of 
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elimination was 2.60 ± 0.60 h. AUC of 56.17 ± 7.33 µg.h/mL was calculated. Bioavailability 
was of 82.33 ± 13.36 %. Milk concentrations after SC administration were maintained above 
the MIC between 1 and 8 h. The Cmax was of 13.19 ± 3.47 µg.mL-1 at 3.42 ± 0.19 h. The half life 
of penetration was 41.97 ± 4.55 min and the half life of elimination 7.57 ± 4.47 h. ratio 
CmaxS:CmaxM and AUCM:AUCS were 1.57 and 1.03 respectively. 
 
Fig. 8. Averaged serum and milk TAP concentrations for six lactating cows following 
intravenous, intramuscular and subcutaneous TAP administration at dose of 25 mg.kg-1 
Parameter Serum IV Serum IM Serum SC Milk IV Milk IM Milk SC 
β (h-1) – Ke (h-1)M 0.40±0.16 0.24±0.05 0.28±0.06 0.21±0.067 0.18±0.07 0.15±0.10 
T½β (h)- T½E(h)M 1.95±0.55 2.88±0.50 2.60±0.60 3.62±0.97 5.31±4.27 7.57±4.47 
Kab(h-1)- KP(h-1)M  14.26±8.72 5.06±2.00 1.23±0.37 0.83±0.10 1.00±0.10 
T½ab -T½PM (min)  6.53 ±6.25 10.09±5.37 36.58±9.72 51.11±6.10 41.97±4.55 
AUC (µg.mL/h) 50.59 ±7.56 68.45±16.27 56.17±7.33 85.77±21.58 75.31±9.85 52.85±17.50 
Cmax (µg.mL-1)  29.38±6.90 19.83±3.57 23.09±3.12 17.05±2.73 13.19±3.47 
Tmax (h)  0.32±0.09 0.72±0.12 2.50±0.29 3.42 ±0.19 3.42±0.19 
Lag time (h)  0.05±0.02 0.15±0.02 1.08±0.51 0.78 ±0.23 1.42±0.34 
F (%)  86.33±19.08 82.33±13.36    
Cmax-S/Cmax-M     1.81±0.64 1.57±0.39 
AUCM/AUCS    1.72±0.47 1.19±0.41 1.03±0.26 
Withdrawal (d)    4.13±1.13 4.79±1.40 3.23±0.86 
Table 10. TAP PKs in serum and milk after its administration at dose of 25 mg.kg-1 by IV, 
IM and SC routes in lactating Holstein cows. Withdrawal is the withdrawal time needed to 
obtain milk with TAP levels of less than 20 ng.mL-1. 
As a conclusion, TAP is a highly bioavailable antibiotic, independently of the administration 
route, it arrives with ease to the mammary gland, reaching high levels there. That is why it 
can be considered an excellent option to use in mastitis therapeutics, especially against 
Gram negative pathogens. It has a bacteriostatic action against a broad range of 
microorganisms, although it may be bactericidal for some species under some conditions, 
and in concentrations 3 to 5 times higher than the bacteriostatic ones. Among the bacteria 
inhibited in vitro by relatively low concentrations of TAP are Clostridium, Corynebacterium 
MIC90
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diphtheriae, Diplococcus pneumoniae, Staphylococcus albus, Streptococcus pyogenes, Streptococcus 
viridans, Bacteroides, Fusobacterium, Bordetella, Brucella, Haemophilus, Neisseria, Pasteurella, 
Shigella and some vibrio strains. Some Bacilli, Erysipelothrix, Staphylococcus aureus and 
Streptococcus faecalis are sensitive to moderate concentrations of TAP (FAO: JECFA 47, 1997). 
When TAP was administered by IMM route in an individual quarter high concentrations in 
the nonmedicated quarters and in serum were determined. Although the experimental 
animals were milked every 12 h, TAP levels above the minimum inhibitory concentration 
for the majority of pathogens were maintained during 36 h in the treated quarter and 
between 8 and 12 h in the nontreated quarters and during less than 4 h in the case of blood 
(Mestorino et al., 1995). TAP passes easily and completely from the treated quarter to the 
homolateral quarter by simple diffusion, to the heterolateral quarters, on the other hand, it 
arrives through circulation. Time elapsed between the administration and the first measured 
concentration (Lag Time) was shorter in the case of the homolateral quarter (rear-left –RL-: 
0.25 h), intermedial in the case of serum (0.54 h) and rear-right –RR- (0.58 h) and longer in 
the case of the front-right quarter –FR- (1.92 h). In the homolateral quarter, the main Cmax 
and the highest bioavailability were recorded. Maximum TAP concentrations of 75.30, 15.06, 
19.03 and 15.79 µg.mL-1 in the RL, FR, RR and serum respectively, and the ratios of 
AUCtreat:AUCnontreat of 10.61, 1.81, 2.78 and 1.35 in the RL, FR, RR and serum respectively, 
suggests that the largest passage takes place from the administered quarter to the 
homolateral one, and that the arrival of TAP to the contralateral quarters is via the blood 
due to that the longitudinal medial intermammary septum is a highly impermeable (Fig. 9).  
 
Fig. 9. Averaged milk and serum TAP concentrations for six lactating cows following IMM 
infusion in the front-left mammary quarter at dose of 25 mg.kg-1. 
4.3 Macrolides 
The prototype of the macrolide class of antibiotics was introduced in 1952 under the name of 
erythromycin. Macrolides are frequently used in Argentina for bovine mastitis treatment, 
since high concentrations in milk are obtained following parenteral administration. 
Erythromicin, oleandomycin, tylosin and the modern tilmycosin, azithromycin and 
tulathromycin have been extensively used in bovines. The last three are drugs with 
substantial improvements respect the older ones.  
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4.3.1 Spiramycin 
Spiramycin (SPM) is a macrolide antibiotic that is active against most of the microorganisms 
isolated from the milk of mastitic cows. SPM is a very soluble weak base (pKa 8.2) which 
crosses lipid membranes with ease. 
Our team investigated the disposition of SPM in plasma and milk after intramuscular 
administration. Lactating Holstein cows with subclinical mastitis caused by S. aureus were 
given two injections of SPM adipate at a dose of 16,000 IU/kg (3.75mg.kg-1) with 24 hours of 
intervals. The experimental animals were allocated by production level (high vs. low 
production) and the quarters were grouped by health state (Fig. 10 A and B).  
In susceptibility studies, usually erythromycin is used as a representative of the macrolide 
group of compounds. However, when evaluating SPM susceptibility, it is not recommended 
to use erythromycin disks, because it has been shown that proteins involved in macrolide-
ribosome interactions are different. The binding site of erythromycin is the L22 protein 
while for SPM the protein is the L27 (Lucas et al., 2007; 2009b). The MIC90 calculated for S. 
aureus field isolates was 4µg.mL-1(17 IU.mL-1) (Lucas et al., 2009b). Other authors have 
reported MICs of 3.25 µg.mL-1 (15 IU.mL-1) (Renard et al., 1996) and 8 µg.mL-1 (Friis et al., 
1988). After IM SPM administration, milk concentrations were higher than those in plasma. 
The maximum concentration in milk (CmaxM) was 3.91µg.ml-1 at 9 hours post-first 
administration and 3.46 µg.ml-1 12 hours post-second administration. Whereas in plasma the 
measured concentrations were far below those in milk (0.12µg.ml-1 at 0.5 h and 0.097µg.ml-1 
at 8 h post first and second administration respectively). An average milk-to-plasma ratio of 
46.35 ± 11.09 was calculated by comparison of the areas under the concentration vs time 
curves. Our results were coincident with other authors (Renard et al., 1996). The level of 
production factor exert a significant effect on Cmax, T½ǌ, AUC0-24, MRT and Fmilk (Table 11). 
SPM in milk of high production animals reached higher concentration with AUC0-24h also 
higher in this group. However, T½ǌ was longer in the milk of low production cows. The 
average milk-to-plasma ratio was higher in high producing cows. Since the milk production 
level has a significant effect on efficacy predictors such as T>MIC90 (41.60) and AUC0-
24/MIC90 (15.87) milk SPM concentrations obtained were insufficient to achieve optimal 
PK/PD relationships.  
4.3.2 Azithromycin 
Azithromycin (AZT) is a semisynthetic compound in which the lactone ring has been 
expanded to a 15-member structure and is considered the prototype of the new macrolide 
structures identified as azalides (Lucas et al., 2007; 2009c). AZT formulations are not 
available for use in production animals but could possess advantages for the treatment of 
certain bovine infections such as those produced in the mammary gland. We performed a 
complete study about its pharmacokinetic behaviour in blood and milk following 
administration by different routes, both in healthy cows and cows with mastitis. The results 
observed after its administration by any of the analyzed routes was typical of the 
macrolides, with low plasma concentrations and very high concentrations in milk and soft 
tissues; a great volume of distribution and a prolonged terminal half-life both in blood and 
milk. The fact that AZT tends to accumulate in inflammatory cells, has a kinetic incidence in 
the results, especially after IMM administration. 
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Fig. 10. (A) Mean concentrations of SPM in mastitic quarters and healthy quarters after two 
doses of 3.75 mg.kg-1 IM with a 24-h interval. (B) Mean concentrations of SPM in plasma in 
high-producing and low-producing cows; and quarters of high-producing cows and low-
producing cows after two doses of 3.75 mg.kg-1 IM with a 24-h interval  
 
Parameter Milk High-Pr Milk low-Pr Plasma High-Pr Plasma Low-Pr 
Cmáx1 µg.mL-1 4.26 ± 0.66 3.57 ± 0.61 0.12 ± 0.01 0.12 ± 0.01 
Tmáx1 h 8.67 ± 2.31 9.33 ± 1.97 0.50 ± 0.00 0.50 ± 0.00 
Cmáx2 µg.mL-1 3.92 ± 0.71 3.01 ± 0.71 0.08 ± 0.02 0.11 ± 0.04 
Tmáx2 h 36.00 ± 0.00 36.00 ± 0. 00 32.00 ± 6.93 32.00 ± 6.93 
T½λ1 h 12.26 ± 2.11 13.64 ± 4.20 27.83 ± 18.,38 25.19 ± 11.03 
T½λ2 h 21.17 ± 8.65 36.60 ± 7.61 7.70 ± 2.06 14.07 ± 5.56 
ABC0-24h µg.h/mL 70. 54 ± 10.62 56.44 ± 8.41 1.77 ± 0.30 2.14 ± 0.42 
ABC0-∞ µg.h/mL 169.76 ± 30.66 171.80 ± 25.61 3.10 ± 1. 14 4.04 ±  0.83 
TMR h 43.54 ± 10.93 55.96 ± 9.83 22.66 ± 0.99 28.78 ± 5.83 
FM  57.73 ± 13.61 43.91 ± 10.30 - - 
Table 11. Milk and plasma PK parameters obtained after two doses of SPM IM 
administration (3.75 mg.kg-1 every 24h) in high and low producing lactating cows.  
Due to the described PK behaviour, AZT proved to be an interesting tool with potential 
for infections in soft tissues, although this should be backed by efficacy trials. Classically, 
macrolides have been considered drugs of choice to treat IMM infections not only because 
of their antibacterial efficacy but because of their favourable PK profile. On the basis of 
these antecedents we decided to investigate the distribution of AZT in plasma and milk 
after IV, IM and IMM administration in healthy and mastitic lactating Holstein cows and 
cows at drying-off (Turic et al., 2003a; 2003b; 2006; Errecalde et al., 2003;Lucas et al., 
2009b; 2009c). 
There are no AZT susceptibility studies on S. aureus isolated from bovine mastitis cases. 
However, there are data for other macrolides. Usually when running antibiograms, an 
erythromycin disk is used to evaluate susceptibility to the macrolide family. Variable 
percentages of macrolide resistant S. aureus ranging from 1.9% to 26.3% have been reported 
in several studies (Ziv., 1980a; Owens et al., 1997; Andrade et al., 2000). At present there are 
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highly specific methods for susceptibility testing of veterinary pathogens (CLSI, 2008). The 
AZT MIC50 calculated for the 51 S. aureus isolations was 0.5 µg.mL-1 and the MIC90 was 1 
µg.mL-1 (Lucas et al, 2009c). Although it is not advisable to compare MICs of different ATM 
agents, it is worth stating that erythromycin MIC90 for bovine isolated S. aureus was reported 
as 0.5 µg.mL-1 in several publications (Gianneechini et al., 2002; Russi et al., 2008). 
The most prominent pharmacokinetic characteristic of AZT is the presence of high tissue 
concentrations which are maintained a long time after serum concentrations decline to very 
low levels (Fig 11 A y B). This characteristic was demonstrated after its IV and IM 
administration (Tables 12 and 13) (Turic et al., 2003a; 2003b), and was coincident with some 
authors in goats (Cárceles et al., 2005) and humans (Foulds et al., 1991). AZT T½ǌ was long, 
an expected finding, according to the characteristics of this ATM. 
Milk AZT levels resulted much higher than those found in serum (Fig. 11 A y B), after each 
IV and IM administration which is a logical finding according to the lipophilicity and wide 
distribution of the drug.  
 
Fig. 11. Mean concentration of AZT in serum and milk of healthy and mastitic lactating cows 
after IV (A) and IM (B) administration (10 mg.kg-1) 
AZT exhibited major penetration into milk and it was cleared rather slowly. PK parameters 
indicated a high retention of the drug in peripheral compartments. The T½ǌ in milk after 
each route of administration was always at least four times longer that in plasma. AZT T½ǌ 
clearly suggested that milk concentrations decrease more slowly than plasma ones. 
Later we performed other assay with AZT, but in this case it was administered 
intramuscularly in two doses of 10 mg.kg-1 body weight with a 48 h interval (Lucas et al., 
2009c). The experimental animals were allocated by production level (high and low 
production levels)  and the quarters were grouped by health  state (Fig. 12 A and B). The T½ǌ 
in milk after first administration was at least four times longer than that in plasma. AZT T½ǌ 
suggested that milk concentrations exhibited a tendency to decrease more slowly than 
plasma ones. The same pattern was observed after a single 10 mg.kg-1 IM dose of AZT to 
lactating Holstein cows (Turic et al., 2003a). 
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Parameter Serum healthy Serum  mastitic Milk healthy Milk mastitic 
λz (h-1) 0.019±0.006 0.013±0.001 0.007±0.003 0.007±0.001 
t½λz (h) 38.6±9.11 53.07±3.36 113.3±39.5 111.2±21.1 
Varea (ml.kg-1) 6325.6±1467.9 6486.3±318.6   
AUC0-∞ (h.µg/ml) 89.0±13.4 84.8±2.65 599.4±141.3 511.2±113.3 
MRT (h) 52.1±8.94 69.5±7.61 163,6±58,6 159,6±34,7 
Tmax (h)   9.0±3.29 12.0±9.86 
Cmax (µg/ml)   3.82±0.49 3.13±0.66 
AUCM/AUCS   389.4±69.4 232.3±52.7 
Table 12. Serum and milk PK parameters obtained after one IV administration of AZT at a 
dose of 10 mg.kg-1 in healthy and mastitic lactating Holstein cows  
Parameter Serum healthy Serum mastitic Milk healthy Milk mastitic 
λz (h 1) 0.018±0.004 0.015±0.003 0.008±0.003 0.005±0.001 
t½λz (h) 39.11±7.64 47.31±9.75 105.19±40.18 135.96±39.49 
AUC0-∞ (h.µg/ml) 36.26±8.59 26.09±1.71 561.89±60.55 713.36±249.99 
MRT (h) 53.43±6.80 63.22±10.92 158.38±54.21 201.03±56.06 
Tmax (h) 3.00±1,549 2.17±0.41 17.33±10.56 13.67±5.13 
Cmax (µg.ml-1) 0.92±0.11 0.66±0.03 4.35±2.17 3.48±0.42 
F (%) 41.38±13.98 18.860±2.51   
AUCM/AUCS   1041.57±516.7 1422.57±350. 
Cmax M /Cmax S   4.85±2.67 5.26±0.73 
Table 13. Serum and milk PK parameters obtained after one IM administration of AZT at a 
dose of 10 mg.kg-1 in healthy and mastitic lactating Holstein cows  
When comparing PK parameters by grouping quarters according to health status, it was 
observed that AZT was eliminated more slowly from and AUC0-∞ was substantially higher 
in mastitic quarters. Although this was an unexpected finding (the pKa partition hypothesis 
suggests the opposite), it is coincident with previously reported data (Turic et al., 2003a). 
Milk pH in the experimental animals ranged between 6.5 and 7.5 with the majority of values 
around 7.0. Average pH from all mastitic quarters was 7.13 ± 0.23 and from healthy quarters 
was 6.90 ± 0.21 (see Table 14). This is a normal finding for animals carrying subclinical 
mastitis. AZT is a weak base with a pKa value of 8.74, as a consequence, by application of 
the Henderson–Hasselbach equation, there would be approximately double AZT molecule 
dissociation in mastitic milk and more than three times in milk of healthy animals in 
comparison with plasma (see Table 14). Alkaline drugs (like AZT) are trapped in acidic 
compartments. This theoretical considerations could not, however, be confirmed by the 
experimental findings reported here. Azithromycin (IM) gave rise to very low plasma 
AUCs, which could be explained by its very high liposolubility and penetration into tissues. 
Although higher AUC was expected in milk of healthy animals (more acidic), which is a 
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common finding with the classic macrolide antibacterials, we found exactly the opposite. In 
our experiment, the highest concentrations were determined in the milk of mastitic animals, 
with an AUCmilk ⁄ AUCplasma ratio extremely high. Our explanation for this unexpected 
finding is the amount of somatic cells (SCC) present in mastitic milk in comparison with the 
normal milk. In the former case, the number of SCC was several times above those in 
normal milk. Mastitic milk normally exhibits very high cell counts as consequence of the 
inflammatory reaction. As it is known, AZT is able to reach high concentrations at infected 
sites, as a result of increased delivery from phagocytes (Lucas et al, 2009c). On this basis, we 
consider that the inflammatory reaction (and the high amount of cells) in the infected 
quarters is the main reason for the differences found between mastitic and healthy quarters.  
 
 Plasma Mastitic milk  Healthy milk 
pH 7.40 7.13 6.90 
Dissociated/non dissociated molecules 21.88/1 40.74/1 69.18/1 
Theoretical ratio of dissociated molecules 1 2.86 3.16 
Experimental Milk/plasma AUC  743.60 482.72 
Table 14. Average plasma pH, milk pH (mastitic vs. healthy), dissociation as a function of 
AZT pKa (8.74), theoretical ratio milk ⁄ plasma and experimental AUC ratio milk ⁄ plasma 
 
Fig. 12 (A) Mean plasma and milk concentrations of AZT in high-producing and low-
producing cows after two 10 mg.kg-1 IM doses with a 48-h interval. (B) Mean concentrations 
of AZT in mastitic quarters and healthy quarters after two 10 mg.kg-1 IM doses with a 48-h 
interval 
A significant AZT fraction could be trapped in the milk-cell compartment without 
participating of the plasma:milk equilibrium, largely dependent on the pKa – pH 
relationship. The AUC0-∞(P ≤ 0.05) and the MRT were higher in whole milk from mastitic 
quarters, which may indicate that the drug is present in higher amounts and persist during 
longer time in mastitic quarters than in healthy ones. At the same time, the Fmilk of AZT was 
higher in the mastitic quarters indicating a different PK profile of AZT depending on the 
quarter status. The previous data, reported after a single 10 mg.kg-1 IM dose of AZT to 
lactating Holstein cows, support our observations (Turic et al., 2003a). The Clmam ⁄ F showed 
that AZT elimination was faster in healthy quarters than in mastitic quarters. Separating the 
(A) (B)
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groups according to median production allowed us to identify observations that may be 
extrapolated to situations of major differences in productive levels (Fig. 12 A). The AUC0-∞ 
was higher in quarters of low-producing cows than in quarters of high-producing cows. It is 
possible that a lower milk production causes a slower antibiotic elimination, with a lower 
Clmam ⁄ F value and more prolonged T½ǌ. On the basis of these results, we could suggest that 
low-producing cows have a high tendency to exceed LMR in milk while high-producing 
cows can eliminate (and dilute) the drug fast enough so as to diminish “contact time” and 
clinical efficacy possibilities. 
AZT is a time dependent bacterial killing antibiotic with prolonged persistence (PAE, 
PASME). Thus, for this group, both t>MIC and AUC24h/MIC ratio play an important role in 
planning the dosage regimens. According to  microbiological results, the MIC for S. aureus 
of bovine udder origin was 0.5µg.mL-1. The AUC24/MIC was greater than 100 in both 
healthy as mastitis cows (Table 15). The times above MIC were longer than 95 h for all cases. 
Six healthy and six mastitic lactating cows received one IMM AZT syringe containing 125 
mg in each mammary quarter for three consecutive milkings; and six healthy and six 
mastitic Holstein cows at drying-off received one IMM AZT syringe containing 500 mg in 
each mammary quarter (Turic et al., 2003a; Errecalde et al., 2003).  
For the study in lactating cows, serum profiles evolved with three peaks and a final 
elimination phase after the last infusion. Serum penetration from milk was fast and the three 
peaks were in the same order of magnitude both in healthy and mastitic animals (Fig. 13 A). 
AUC serum concentration was however higher in healthy animals than mastitic animals. 
This resulted an unexpected finding, since AZT is a basic drug. No significant differences 
were found either in T ½ ǌ or MRT between healthy and mastitic animals.  
 
Parameters Mastitic ± SD Healthy ± SD H-prod ± SD L-prod ± SD 
AUC0-24h/MIC90 156.53 ± 39.68 152.46 ± 33.19 152.53 ± 38.93 155.11 ± 31.51 
T>MIC90 96.09 ± 0.74 96.48 ± 1.20 95.83 ± 0.00 96.88 ± 1.80 
*MIC90 of AZT against the 51 S. aureus isolated 
Table 15. PK ⁄ PD parameters of AZT in mastitic and healthy quarters; and in quarters of 
high-producing cows and quarters of low-producing cows after two 10 mg. Kg-1 IM doses 
with a 48-h interval 
4.3.2.1 AZT IMM administration 
Milk profiles, on the other hand, showed interesting differences. Peak concentrations 
resulted much higher in mastitic animals (Fig. 13 A). T ½ ǌ and MRT resulted in the same 
order of magnitude in both groups and the differences lacked statistical significance. Areas 
under the curves, however, showed major differences. In the case of the healthy animals 
AUC0-∞ was in the order of 503.03 and 1615.65 µg.h.mL-1 in mastitic animals, the difference 
being statistically significant (Table 16). This difference in AUC was coincident with the 
differences found in serum, although these were not statistically significant. 
Once again we found higher AZT concentrations in milk of mastitic animals than in milk of 
healthy animals after IMM administration, similarly as the situation occurred after IM 
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administration. As AZT is so penetrating in tissues and cells, and mastitic milk is so rich in 
somatic and inflammatory cells, the drug becomes included into the more acidic cellular 
compartment, thus hindering its participation in the milk-serum diffusion process (despite 
its pKa), and this retains high amounts of AZT in milk by cell trapping. All this evidence 
supports the fact that AZT is a penetrating azalide with concentrations several times higher 
in tissues and milk than in plasma. If we observe the ratios AUC(milk)/AUC(serum) and we 
compare them with those obtained when the drug was administered intramuscularly we 
could conclude that the high availabilities in milk compared to those of serum are 
independent of the route of administration. 
But, in the study with cows at drying-off, we found some differences: AZT milk 
concentrations in mastitic and healthy animals were similar (Fig. 13 B and Table 17). One 
explanation for this is that physiology of the mammary gland during the dry period differs 
markedly from that during lactation. Very few cells (less than 2% are epithelial cells) and 
total leukocyte concentration increase rapidly in early involution and the milk fat and casein 
may decrease the leukocytes phagocytic function. 
 
Fig. 13. Mean serum and milk AZT concentrations after one IMM AZT syringe containing 
125 mg in each mammary quarter for three consecutive milkings in healthy and mastitic 
lactating cows (A). Mean serum and milk AZT concentrations after IMM syringe containing 
500 mg in each mammary quarter of healthy and mastitic cows at drying off (B). 
Finally, the excellent milk availability observed allows us to consider AZT as a potential 
antimastitic drug, although we have to fit the dosage through PK-PD modeling and 
corroborate with efficacy studies in the future. As was mentioned in previous paragraphs, 
the site where the pathogen is located represents one of the real challenges of ATM 
chemotherapy of the mammary gland. The pathogen can be in milk, or tissues. In the last 
case it can be in the interstitium or in cells. And in this case it can be in the cytoplasm or in 
fagolysosomes. As can be easily understood the deeper the location of the microorganism 
the more difficult will be to reach it by the ATM. Furthermore, if the ATM reaches the site of 
the microorganism, it has to exert its antibacterial effect and to do this it needs some special 
conditions, being the pH a critical one. And the pH becomes more acidic the deeper in 
tissues and cells it is measured. As illustrative figures we can mention the pH of plasma of 
7.4, of interstitium 7.0, of cytoplasm 6.5 and of fagolysosome of 5.0. We evaluated the effect 
of the pH variation on the antibacterial activity of AZT against strains of S. aureus isolated of 
mastitic quarters. S. aureus strains isolated and S. aureus ATCC 25923 were tested at pH 7.4, 
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6.5 and 5.0, in order to simulate the conditions of acidity of plasma, tissue and subcellular 
structures which are commonly associated with S. aureus intracellular persistence. The 
results at pH 7.4, were consistent with those reported by CLSI 2008 (MIC: 1Ǎg.mL-1). 
However, MIC was approximately 16 times higher at pH 5.0 than at pH 7.4 (Fig. 14).  
 
Parameter Serum           
healthy 
Serum  
mastitic 
Milk  
healthy 
Milk   
mastitic 
λz ( h 1) 0.078±0.04 0.050±0.02 0.01±0.00 0.02±0.00 
t½λz (h) 11.76±7.31 16.20±7.20 59.67±12.48 46.85±20.87 
AUC0-∞ (h.µg/ml) 3.51±2.25 2.74±1.11 503.03±49.47 1615.65±501.9
MRT (h) 17.37±10.56 24.69±11.20 76.37±18.32 52.41±28.39 
Tmax (h) 22.75±0.27 22.67±0.26   
Cmax (µg/ml) 0.23±0.05 0.13±0.02   
F (%) 2.03±1.50 1.06±0.43   
AUCM/AUCS   143.31 589.65 
Table 16. Serum and milk PK parameters obtained after one IMM AZT syringe containing 
125 mg in each mammary quarter for three consecutive milkings in healthy and mastitic 
lactating Holstein cows  
Parameter Serum               
healthy 
Serum   
mastitic 
Milk   
healthy 
Milk   
mastitic 
λz ( h1) 0.02±0.01 0.08±0.03 0.01±0.00 0.01±0.00 
t½λz (h) 34.73±10.96 10.18±4.77 107.60±27.72 99.09±28.46 
AUC0-tlas (h. µg/ml) 3.53±1.28 1.35±0.81 760.00±196.3 747.16±223.94 
AUC0-∞ (h.µg/ml) 6.73±2.31 2.12±1.14 1136.11±262. 1056.71±171.4
MRT (h) 15.09±3.15 6.87±1.82 131.18±35.31 122.51±46.32 
Tmax (h) 1.25±0.61 2.08±2.18   
Cmax (µg/ml) 0.22±0.08 0.21±0.19   
F (%) 4.36±1.52 1.14±0.67   
AUCM/AUCS     
Table 17. Serum and milk pharmacokinetic parameters obtained after one IMM AZT syringe 
containing 500 mg in each mammary quarter of healthy and mastitic Holstein cows at 
drying off  
4.3.3 Tylosin 
Tylosin (TYL), other antibiotic of the macrolide group, is commonly used in food animal 
practice. Because it is an organic base (pKa = 7.1), moderately bound by serum proteins 
(40%), with a high degree of lipid solubility (Lucas et al., 2007), TYL would be expected to be 
widely distributed in body fluids and tissues. The MIC of TYL for S. aureus was <1 µg.ml-1 
for most isolates studied. We determined the elimination milk profile of TYL after IM 
administration at multiple dose schemes.  
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Fig. 14. Inhibition of S. aureus exposed to different concentrations (expressed as Log10) of 
AZT (0.25 MIC; 0.5MIC; 1MIC; 2MIC; 4MIC and 8 x MIC) in function of the time and the 
medium pH (5; 6.5 and 7.4) 
 
Parameter Mean SD 
ǌ h-1 0.095 0.028 
T½ǌ h 7.873 2.232 
AUC0-t µg.h/mL 141.360 23.290 
AUC0-∞ µg.h/mL 142.458 23.512 
MRT h 78.395 3.380 
 
Fig. 15. Milk concentrations of TYL after its multiple (five doses every 24 hours) IM 
administration (10 mg.kg-1) 
The objective was to calculate the withdrawal time in milk necessary for TYL to reach 
acceptable limits for human consumption. Healthy Holstein lactating cows received 5 
intramuscular doses of TYL at 10mg.kg-1 every 24 hours (Figure 15). Milk samples were 
obtained from the four mammary quarters before the start of treatment, during and post-
treatment every 12 hours until to 216 hours. The withdrawal time was calculated using the 
harmonized Time to Safe Concentration (TTSC) recommended by the European Union. The 
time required for milk to carry TYL concentration below the maximum residue limits (MRL 
50 ppb) was 120 h post last TYL dose. 
4.4 Tetracyclines 
Oxytetracycline (OTC) is the most representative member of this class of ATMs. OTC is 
widely used in veterinary medicine worldwide. Its use is widespread due to its broad 
spectrum (not only against bacteria but also against some chlamydia, rickettsia and 
protozoa), and certain PK properties as its wide distribution throughout the body and 
prolonged therapeutic effects of some long-acting formulations. Our team has performed a  
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review of clinical aspects and major PK characteristics of the preparations commercially 
available (Mestorino & Errecalde, 1997). The PK of OTC has been studied by several authors 
(Schifferli et al, 1982, Errecalde, 1992; Errecalde et al, 1997). The new long-acting 
formulations have allowed the maintenance of high concentrations for periods much longer 
than the classical preparations, which represented a significant change in the practicity and 
in the usage habits, but also in maintaining residual levels for long periods in different 
tissues. Moreover, these formulations result in a significantly longer persistence of milk 
concentrations. The popularity of these preparations is extended to virtually all types of 
exploitation. Although the use of these long acting formulations is justified especially in 
extensive cattle exploitations, in other kind of management (i.e. more intensive), where the 
animals can be daily treated and controlled, is not justified. The use of tetracyclines with 
long elimination half-lives in dairy cows has impacted on repeated violations of maximum 
permitted levels of these antibiotics in milk. Problems that may emerge from the misuse of 
antibiotics are especially related to the presence of sub-therapeutic concentrations and the 
resultant emergence and dissemination of bacterial resistant strains in both animals and 
humans. Indisputably, the possibility of transference of portions of DNA carrying genes 
encoding resistance between bacteria is one of the issues of major concern to people with 
different responsibilities in the area. Direct toxicity must not be discarded. 
Tetracyclines achieve milk concentrations that are approximately in the range of those of 
blood. They are second-choice parenteral antibiotics for serious infections of the udder 
caused by Gram positive organism and possibly by coliforms, although susceptibility 
among the later is controversial. In previous studies we evaluated the serum and milk PK 
behaviour of OTC after administration of therapeutic doses of three commercially available 
preparations at 5, 10 and 20 % by the IM route. In Figure 16 A and B, the plasma and milk 
OTC concentrations after IM administration of three different formulations is represented. 
 
Fig. 16. Serum (A) and milk (B) OTC concentrations after IM administration of three 
different formulations to milk cows in production. 
The 20% solution presented the higher area under the curve milk concentration versus time 
and the longest elimination half-life (Table 18). The withdrawal periods from milk for the 
5%, 10% and 20% solutions resulted 3.5, 5 and 8 days respectively. 
Addition of milk to Mueller-Hinton susceptibility test medium permitted measurement of 
milk effect on agar disc diffusion zone diameters obtained from S. aureus field  isolates and 
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stock strains. Milk reduced the activity of different ATM agents, as novobiocin, 
streptomycin, gentamycin, tetracycline, and vancomycin (Owens & Watts, 1987). As was 
previously said, MIC is used in conjunction with PK data to determine the more appropriate 
surrogate PK/PD parameter. Problems arise in vivo, however, due to the physiological 
status of the host, site of infection, and properties of the ATM. Often, the concentration of 
active ATM at the infection site is quite different from that in serum or milk. Antimicrobial 
concentrations are lower in ischemic areas, scar tissue, and abscess contents. Also, pH, 
protein binding, and also normal metabolism and renal excretion mechanism reduce 
concentration of available ATM (Thornsberry and Sherris, 1985). Standard susceptibility 
tests measure ATM effectiveness in conditions extremely different from those in the udder. 
 
Parameters 
OXT 5% OXT 10% OXT 20% 
Serum Milk Serum Milk Serum Milk 
Mean±SD Mean ±SD Mean ± SD Mean ±SD Mean ±SD Mean ±SD 
Cmax (µg.ml-1) 2.94±0.74 2.46±0.49 3.37±0.54 2.35±0.27 3.39±0.43 2.30±0.33 
Tmax (h) 3±0 9.50±1.91 7.50±1.91 9.00±1.15 6.25±3.30 17.50±7.55 
ß (h-1) 0.035 ±0.02 0.0490.018 0.037±0.018 0.0240.006 0.022±0.007 0.0250.017 
T½ ß (h) 23.06±8.53 16.167.31 22.94±13.04 31.1610.16 34.07±11.00 36.7417.61 
MRT (h) 33.68±12.01 29.97±11.96 33.35±16.07 51.88±16.19 52.21±11.85 64.94±19.57 
AUC (µg.ml/h) 92.72 ±26.77 62.6713.60 114.64 ±32.81 125.21 21.18 196.05 ±32.50 166.43 28.10 
AUC0-24 
(µg.ml/h) 
 32.51±7.59  40.49±6.03  43.14 ± 6.88 
CmaxS/CmaxM  1.19  1.43  1.47 
AUCM/AUCS  0.68  1.09  0.85 
Table 18. Serum and milk PK parameters obtained after administration of three OTC 
formulations in Holstein healthy lactating cows 
In bovine mastitis, the unique environment of the mammary gland presents a problem for 
determining usefulness of chemotherapeutic agents against a given organism. Milk proteins, 
lipids, pH, and ionic characteristics can reduce concentration of active ATM (Ziv, 1980a). A 
simple in vitro method for determining the effect of milk on ATM activity could be of use 
when examining ATMs for possible use in mastitis therapy (Owens & Watts, 1987).  
The MIC90 of tetracycline (used as group representative) among S. aureus determined by 
different authors was between 0.5 - 1 µg.mL-1 (Pol and Ruegg, 2007). If we consider than the 
MIC of tetracycline in milk could increase 4 to 32 times that in MH, the S. aureus mastitis 
treatment with OTC has not real possibilities of success, because the OTC concentrations 
reached in milk are insufficient for achieving the appropriate PK/PD predictors of 
therapeutic efficacy against S. aureus (AUC24/MIC>100). An irreversible binding between 
tetracycline and large molecules of milk, which might be due to a hydrophobic interaction, 
was demonstrated by a dialysis test, suggesting the observed impairing effect was due to 
the action of milk on the tetracycline being tested. Further investigation revealed that much 
of the reduction of tetracycline activity in milk was attributable to the milk protein casein, 
while other heat-sensitive components in milk also play some roles (Kuang, et al., 2009). 
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4.5 Fluoroquinolones  
Enrofloxacin (ENR) is a quinolone widely used for treatment of various infectious diseases 
in cattle caused both by Gram-positive and Gram-negative bacteria, but is not specifically 
recommended for bovine mastitis treatment; although high concentrations are reached and 
maintained in milk following parenteral administration. The MIC90 value found by Russi et 
al., (2008) was similar than the reported for isolates from Uruguay and (Gianneechini et al., 
2002; San Martín et al., 2002). 
4.5.1 Danofloxacin  
Danofloxacin (DAF) is a fluoroquinolone (FQ) ATM drug developed for use in veterinary 
medicine. DAF shows a broad spectrum of activity against most Gram-negative, Gram-
positive bacteria and mycoplasma, but has poor activity against anaerobes (Shojaee Aliabadi 
& Lees, 2003). FQ share some characteristics such as a broad spectrum of bactericidal 
activity, a large volume of distribution, low plasma protein binding and relatively low 
minimal inhibitory concentrations (MICs) against target microorganisms (Otero et al., 2001a; 
2001b; Mestorino et al., 2009). Danofloxacin 18% was demonstrated to be effective in the 
treatment of bacterial pneumonia caused by P. multocida, M. hemolytica and H. somnus  or 
bacterial enteritis (Mestorino et al., 2009) given as a single injection at a dose rate of 6 mg.kg-
1 of body weight, or two doses 48 hours apart, as needed. This formulation has the 
advantage of being safe and effective with a single dose or at maximum two doses, as 
handling animals many times for treatment is not practical. The concept of the high dosage 
in a single injection is that, after injection, the drug is available in high concentrations 
sufficient to kill all the sensitive bacteria during a relatively short period of time (Mestorino 
et al., 2009). This reduces the selection pressure for resistance. These characteristics suggest 
that it could be useful for the treatment of bovine mastitis caused by S. aureus. In order to 
investigate this possibility, the PK profile of DAF 18% was studied in plasma, milk and 
various tissues in dairy cows, when administered as a single subcutaneous injection at a 
dose of 6mg.kg-1 (Fig. 17 A, B, C and D). DAF was rapidly absorbed and reached peak 
plasma concentrations of 0.53 g.ml-1 within 2 hours after injection. Distribution of DAF 
from plasma to all sampled tissues and milk was extensive (Table 19). Peak milk 
concentrations of 1.37g.ml-1 were achieved 8 hours post-injection. Maximum 
concentrations (9.73 g.g-1) in udder tissue (average of 4 quarters) and uterus (2.53 g.g-1) 
were achieved 6 and 4 hours after injection, respectively. Maximum concentrations in 
intestinal tract tissue and lymph nodes ranged from 3.6 g.g-1 (duodenum) to 10.22 g.g-1 
(lymph nodes), and were reached between 2 h and 12 hours after injection. Plasma area 
under the curve (AUCpl) was 9.69 g.h/ml. Plasma elimination half life (T½ß) was 12.53 h. 
DAF has a very high volume of distribution (Vd = 5.79 l.kg-1). AUC values for the various 
tissues and milk greatly exceeded AUCpl. Elimination half life from milk and tissues 
varied between 4.57 hours to 21.91 hours and the milk withdrawal time was 73.48 h (Table 
19). The reported results support the potential use of DAF in the treatment of mastitis and 
other infections in milk cows with three days of withdrawal.  
Later we performed other study in cows with subclinical mastitis, who received 10 mg.kg-1 
subcutaneous (SC) 18% DAF(Fig. 18). The MIC50 calculated for S. aureus isolated from 
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bovines with subclinical mastitic was 0.25 µg.mL-1 and the MIC90 was 1 µg.mL-1. Gram-
negative bacteria have a MIC range of 0.05-2.5 µg.mL-1, while for Gram-positive bacteria it 
was 0.25-5 µg.mL-1 (Shem-Tov et al, 1998). Although, there are no references for DAF MIC 
against S. aureus, it has been proved that enrofloxacin MIC is ≥1 µg.mL-1 (Cester et al, 1992). 
The MIC90 was determined in order to calculate PK/PD parameters. Milk maximum 
concentration (Cmax) was 2.99 ± 0.88 µg.mL-1 (6.13 h post-administration)  whereas plasma 
Cmax was 1.45 ± 0.26 µg.mL-1 (1.17 h post-administration). DAF was eliminated with mean 
half-lives of  7.56 ± 2.53, and 4.43 ± 1,36 h from milk and plasma respectively. The mean area 
under the concentration versus time curve from 0 to 24 hours (AUC0-24h) was 34.84 ± 10.97 
µg.h/mL in milk and 8.71 ± 1.14 µg.h/mL in plasma.  
 
Parameter Plasma X SD Milk X SD
ß (h-1) 0.06 0.01 0.15 0.02
T½ ß (h) 12.53 1.47 4.57 0.46
Kabs (h-1) 1.46 0.91 0.32 0.06
T½ abs (h) 0.64 0.39 2.27 0.48
MRT (h) 18.38 2.52 8.34 1.31
Cmax (µg.mL-1) 0.53 0.13 1.37 0.73
CmaxM/CmaxPL --- --- 2.68 1.35
T½ßM/T½ßPL --- --- 0.37 0.08
Tmax (h) 2.17 0.98 8.67 2.07
AUC (µg.mL/h) 9.69 1.41 15.46 5.42
WT (h) 73.48
Table 19. DAF PK parameters (mean ± SD) obtained in plasma and after its subcutaneous 
administration (6 mg.kg-1) 
When comparing PK parameters by grouping quarters by level of production, it was 
observed that DAF was eliminated more slowly from quarters of low-producing cows (Fig 
18 B). Concomitantly, the MRT in milk from quarters of low-producing cows was higher 
than the MRT determined in milk from quarters of high-producing cows.  
FQ are considered to have a concentration-dependent effect, although a time dependent 
bactericidal effect against some Gram-positive bacteria has also been described (Cester et al. 
1996). DAF exhibited the same behavior against S.aureus, because it was strongly 
bactericidal at higher concentrations and when increases contact time. Importantly, the 
potency of DAF, evaluated by the MIC, is not affected by pH changes (Fig.19). The WT 
resulted longer in milk of low production than in milk of high production cows. Separating 
the groups according to the health status (Fig 18 A), it was observed that there were no 
statistically significant differences between the PK behaviour in both groups. The level of 
production had a significant effect (P < 0.05) on the milk elimination half-life (T½) and on 
the mean residence time (MRT) of DAF in milk. The infection presence in the mammary 
quarters had a significant effect (P < 0,05) on Tmáx and MRT  in milk. The incidence of 
infection and level of production on the PK of danofloxacin in milk cows have to be 
considered when designing dosage regimens for this drug. 
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(A) (C) 
 
(B) (D) 
Fig. 17. Mean DAF plasma and milk concentrations (A). Mean DAF mammary, uterus and 
plasma concentrations (B), mean DAF duodenum, jejunum, ileum, large intestine vs. plasma 
concentrations (C) and mean DAF mesenteric lymph nodes vs. plasma concentrations (D), 
each after its SC administration in lactating cows  
5. Perspectives for new therapeutic formulations 
As described, S.aureus represents a major problem in bovine mastitis because of the poor 
cure rate despite the in vitro susceptibility of the acting bacteria. One possible reason for this 
is its intracellular location within the udder phagocytes, a place difficult to access for the 
majority of ATMss, wich combines with reduced activity at the acidic pH of lysosomes. 
Other possible obstacle for antibacterial efficacy is the non-diffusion of acidic antibiotics 
through the lysosomal membrane due to their ionic presentation at extracellular (7.4) or 
cytoplasmic (6.5) pH and the very poor retention in cells of antibiotic which penetrate freely 
such lincomycins. Consequently, there is a clear need for more specialized dosage forms to 
be developed for use in the treatment of S. aureus bovine mastitis. Indeed, in view of the 
magnitude of the economic losses, every effort to develop new dosage forms should be 
undertaken. Such new formulations should be designed to counteract the causes of failure of 
antibiotic therapy for S.aureus and should have the following features (Gruet et al., 2001): 
 Ability to penetrate phagocytes  and to be retained in cells for adequate  time; 
 No substrate or low metabolism in the cells; 
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 Effective at low pH against S. aureus; 
 Administration  via local infusion through the  teat canal 
  
Fig. 18. (A) Mean concentrations of DAF in mastitic quarters and healthy quarters after 10 
mg.kg-1 IM dose (B) Mean plasma and milk concentrations of DAFin high-producing and 
low-producing cows after 10 mg.kg-1 IM dose. 
 
Fig. 19. Inhibition of S. aureus exposed to different concentrations (expressed as Log10) of 
DAF (0.25 MIC; 0.5MIC; 1MIC; 2MIC; 4MIC and 8 x MIC) in function of the time and the 
medium pH (5; 6.5 and 7.4) 
Delivery systems such as injectable microparticles or colloidal suspensions could fulfill 
some of the expectations for a new dosage form for IMM infusion. Microparticles are 
small, spherical particles with a diameter larger than 5µm, and can be made out of natural 
(gelatin or alginate) or synthetic material. Only the smallest could potentially be taken up 
by the phagocytes and therefore offer therapeutic value against intracellular bacteria. 
Colloidal suspensions include liposomes and nanoparticles. Both types are spherical 
particles with an average diameter of between 0.05 µm and <5µm. Liposomes are 
phospholipidic particles with an aqueous core. Due to their amphiphilic structure, they 
can incorporate either lipophilic or hydrophilic compounds. Nanoparticles are polymeric 
particles. 
Thus liposomes, microparticles and nanoparticles may be considered potential delivery 
systems in the treatment of bovine mastitis by S. aureus since they may be taken up by the 
phagocytes liberating the active once inside. From the available literature, microparticles 
appear to be the most appropriate candidates for clinical trials in cows. Bodmeier et al. 
(1997) have reported the preparation of ceftiofur microparticles for the purpose of 
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administration to cows at drying off. The microparticles exhibited a good encapsulation 
ratio and were shown in vitro to release the drug slowly over a long period of time. This 
dosage form could be considered an example of possible paths to follow looking for suitable 
new therapeutic systems. 
6. Conclusion 
Milk producing cows are a very special kind of animal. An average good level of milk 
production is in the order of 5% of body weight daily, but everyday more “top” producers 
are rounding 10%. These are values that years ago were considered impossible to reach. 
The huge milk production increase was due to a very efficient process of selection. But 
these processes of increase of milk production pushed these animals to the border 
between physiology and pathology. In these conditions slight modifications in the diet, 
environment and management can result in defensive disequilibrium and disease. It has 
to be noted that the defensive aspects of the mammary gland did not receive the same 
attention than production itself, and, as a consequence, the higher the level of production, 
the higher the risks of mammary pathology. The mammary gland is a rather 
immunologically weak organ, the phagocitic activity in the mammary gland is poor. 
During the first few hours after milking, neutrophils coming into the gland are active, 
however, in a short time, they become to “engorge” with lipid molecules and their activity 
slows. At the end of the intermilking interval, phagocytes are almost inactive. Dilution of 
defensive elements in great producers is another factor. A special consideration has to be 
made when S. aureus is present. This bacterium has the ability of penetrate cells and to 
reproduce very slowly there. The majority of ATMs have serious difficulties to penetrate 
cells, and, if they reach the site where bacteria are, they fail acting against slowly growing 
organisms or low pH. The combination of these factors constitutes a complex problem. 
The knowledge of PK and PD of the different ATMs in consideration of the physiological 
characteristics of the mammary gland can contribute to a more rational use of ATMs. In 
the present paper we presented some data on the behaviour of some ATMs in milk 
producing cows. The consideration of the available data in a frame of prudent use surely 
will increase the number of therapeutically positive results with less possibilities of 
emergence and dissemination of resistant bacterial strains. 
Antibiotic therapy is an essential component in programs of mastitis control, but does not 
replace preventive hygienic measures. A rational approach to ATM treatment involves 
knowing the different variables that influence the outcome of therapy. Accordingly, it is of 
fundamental importance to determine what type of  etiological agents are predominant in 
each farm, which are their susceptibilities and what drugs can be used to combat them, 
having a special consideration on the  penetration and tissue distribution in the mammary 
compartment, penetration  into cells, and ATM activity once in the target place. 
The increase in the knowledge of the microbiology and pathophysiology of mastitis by S. 
aureus, together with the new tools to model PK and PD of ATMs will contribute to the 
design of new administration systems and therapeutic plans with improvement of clinical 
and microbiological efficacy without the emergence and dissemination of resistant 
microorganisms. 
www.intechopen.com
 
A Bird's-Eye View of Veterinary Medicine 
 
466 
7. References 
Andes D. Stamsted T. & Conklin R. (2001) In-vivo pharmacodynamics of amphotericin B 
against Candida albicans. Antimicrobial agents and chemotherapy 2001 March; 45:922-
926 ISSN 1098-6596 
Andes K. & Craig W.A. (2002) Pharmacodynamics of the new fluoroquinolone gatifloxacin 
in murine thigh and lung infection models. Antimicrobial Agents and Chemotherapy, 
Vol. 46, No. 6 (June 2002), p. 1665-1670, ISSN: 1098-6596 
Andrade, M.A., de Carvalho Dias Filho, F., de Mesquita, A.J. & Tironi Rocha, P. (2000) 
Sensibilidade in vitro de Staphylococcus aureus isolados de amostras de leite de 
vacas com mastite subclínica. Ciencia Animal Brasileira, June 2000, 1, 53–57. ISSN: 
1089-6891 
Archimbault, P. & Boutier C. (1981). Amoxicilline chez le veau: Biodisponibilité comparée de 
préparations injectables. Revue Med Vet. 132, 51-56. ISSN 0035-1555, OCLC: 
6274197 
Baggot J.D. (1986) Principios de farmacología clínica veterinaria. 1 ed. España: Acribia S.A.; 1986. 
ISBN.: 978-84-200-0566-9 
Baggot JD, Love DN, Stewart J & Raus J. (1988). Bioavailability and disposition kinetics of 
amoxicillin in neonatal foals. Equine veterinary journal (Mar 1988) 20, 125-127. ISSN: 
0425-1644. 
Bodmeier R., Huagang C., Davidson R.G.W., & Hardee G.E. (1997) microencapsulation of 
antimicrobial ceftiofur drug, Pharmaceutical development and technology. 4, 323-334. 
ISSN 1097-9867 
Brouillete E., Grondin G., Lefebvre C., Talbot B.G. & Malouin F. (2004) Mouse mastitis 
model of infection for antimicrobial compound efficacy studies against intracellular 
and extracellular forms of Staphylococcus aureus. Veterinary microbiology 101(4) (2004 
Aug): 253-262. ISSN: 0378-1135. 
Cárceles, C.M., Font, A., Espuny, A., Fernández-Varón, E., Serrano, J.M. & Escudero, E. 
(2005) Pharmacokinetics of azithromycin after intravenous and intramuscular 
administration in goats. Journal of veterinary pharmacology and therapeutics, 28, 51–55. 
ISSN: 0140-7783 
Cerca N., Martins S., Cerca F., Jefferson K., Pier G., Oliveira R., & Azeredo J. (2005) 
Comparative assessment of antibiotic susceptibility of coagulase-negative 
staphylococci in biofilms versus planktonic culture as assessed by bacterial 
enumeration or rapid XTT colorimetry. Journal of Antimicrobial Chemotherapy 56 (2) 
(May 2005): 331-336. ISSN 1460-2091 
Cester, C., Schneider, M. and Toutain, P. 1996. Comparative kinetics of two orally 
administered fluoroquinolones in dog: Enrofloxacin versus Marbofloxacin. Revue 
de Medicine Veterinaire; 147:703-716. ISSN: 0035-1555 
CLSI (2008) Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial 
Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals; Approved 
Standard, 3rd edn. CLSI document M31-A3. CLSI, Wayne, USA. 
Constable P.D. & Morin D.E. (2002). Use of antimicrobial susceptibility testing of bacterial 
pathogens isolated from the milk of dairy cows with clinical mastitis to predict 
response to treatment with cephapirin and oxytetracycline. J.Am Vet med Assoc 221 
(1) (July 2002):103-108. ISSN 0003-1488 
Craig W.A. & Dalhoff A. (1998). Pharmacodynamics of fluoroquinolones in experimental 
animals, p. 208-232. In J. Kuhlman, A. Dalhoff, and H. J. Zeiller (ed.), Handbook of 
www.intechopen.com
 
Pharmacokinetic-Pharmacodynamic Considerations for Bovine Mastitis Treatment 
 
467 
experimental pharmacology, vol. 127. Quinolone antibacterials. Springer-Verlag, 
Berlin, Germany. ISBN: 3540625127 
Craig W.A. (1993). Post-antibiotic effects in experimental infection models: relationship to in 
vitro phenomena and to treatment of infections in man. Journal of Antimicrobial 
Chemotherapy 31, Suppl D, 149-158. ISSN 1460-2091 
Craig W.A. (2001) Antimicrobial Pharmacodynamics in theory and Clinical Practice. Edited by 
Ch.H. Nightingale, T. Murakawa and P.G. Ambrose. Marcel Dekker, Inc. Cap. 1: 
Pharmacodynamics of Antimicrobials: General Concepts and Applications, p1-28. 
ISBN 0-203-90837-6 
Drusano G.L. (2004). Antimicrobial pharmacodynamics: critical interactions of “bug and 
drug”. Nat Rev Microbiol (April 2004) 2(4):289-300. ISSN 1740-1534 
Drusano G.L., Johnson D.E., Rosen M. & Standiford H.C. (1993) Pharmacodynamics of a 
fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas 
sepsis. Antimicrobial Agents and Chemotherapy. 37, 1993 March: 483-490. ISSN: 1098-
6596 
Errecalde J.O. (1992). Tissue concentrations of a long-acting oxytetracycline formulation 
after intramuscular administration in cattle. Revue scientifique et technique 
(International Office of Epizootics) 1992 Sep;11 (3):909-15. ISSN:0253-1933 
Errecalde JO, Mestorino ON, Mariño E (1997). Effects of the calculation methodology in the 
evaluation of oxytetracycline pharmacokinetic parameters after its intravenous 
administration to calves. Veterinary Research Communications 21(9): 273-281. ISSN 
0165-7380 
Errecalde J.O., E Turic, J Pesoa, & N Mestorino. (2003). Azithromycin Serum and Milk 
Concentrations After Its Intramammary Administration In Healthy And Mastitic 
Lactating Cows. Journal of Veterinary Pharmacology and Therapeutics. Volume 26, 
supplement 1, 135. ISSN: 0140-7783 
Errecalde J.O. (2004) Uso de antimicrobianos en animales de consumo. Incidencia del 
desarrollo de resistencias en salud pública. Organización de las naciones unidas 
para la agricultura y la alimentación (FAO - Roma), Study 162, 57 pp. ISBN 92-5-
305150-7.  
Erskine R.J., S. Wagner; F.J DeGraves (2003) Mastitis therapy and pharmacology. The 
Veterinary clinics of North America. Food animal practice. Mar 2003; 19(1):109-38, vi. 
ISSN 1558-4240 
Erskine R.J., Walker R.D., Bolin C.A., Bartlett P.C., and D.G. White. 2002 a. Trends in 
antibacterial susceptibility of mastitis pathogens during a seven-year period. J 
Dairy Sci. May; 85(5):p.1111-8 
Erskine RJ. (2002b) Empleo de Fármacos antimicrobianos en la mastitis bovina. Terapéutica 
Antimicrobiana en Medicina Veterinaria. En: Prescott JF, Baggot JD, Walter RD, 
editores. Terapéutica antimicrobiana. 3 ed. Buenos Aires, Argentina: Intermédica; 
2002b. p. 613-642. ISBN: 9505552564  
FAO. Food and Nutrition Papers. 1997. Residues of some veterinary drugs in animals and 
foods.Abamectin, chlortetracycline and tetracycline, clenbuterol, cypermethrin, 
moxidectin neomycin oxytetracycline, spiramycin, thiamphenicol, tilmicosin, 
xylazine. (JECFA 47). ISSN 0254-4725 
Finberg R.W., Moellering R.C., Tally F.P., Craig W.A., Pankey G.A., Dellinger E. P., West 
M.A., Joshi M., Linden P.K., Rolston K.V.,  Rotschafer J.C. & Rybak M.J. (2004). The 
importance of bactericidal drugs: future directions in infectious disease. Clinical 
Infectious Diseases 39 (9), November 2004: 1314-1320. ISSN 1537-6591. 
www.intechopen.com
 
A Bird's-Eye View of Veterinary Medicine 
 
468 
Firsov A.A. Shevchenko A.A., Vostrov S.N. & Zinner S.H. (1998). Inter- and intraquinolone 
predictors of antimicrobial effect in an in vitro dynamic model: new insight into a 
widely used concept. Antimicrobial Agents and Chemotherapy, Vol. 42, No. 3, March 
1998, p. 659-665, ISSN: 1098-6596 
Firsov A.A. Vostrov S.N., Kononenko O.V., Zinner S.H. & Portnoy Y.A. (1999) Prediction of 
the effects of inoculums size on the antimicrobial action of travafloxacin and 
ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro 
dynamic model. Antimicrobial Agents and Chemotherapy, Vol. 43, No. 3, March 1999: 
498-502, ISSN: 1098-6596 
Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. 1993. 
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. 
Antimicrobial Agents and Chemotherapy 1993 May; 37(5): 1073-1081. ISSN: 1098-
6596 
Foulds G., Chan, K.H.; Johnson, J.T.; Shepard, R.M.; Johnson, R.B. (1991). Concentrations of 
azithromycin in human tonsillar tissue. European Journal Clinical Microbiology 
Infections Disease. 10 (10):853-856. ISSN:1198-743X  
Franklin A. (1998). Antibiotic policy and ocurrence of resistance in Sweden. Proceedings of 
25th International Dairy Congress, Aarhus, Denmark, 229-234. 
Friis C, Erhardsen E, Bisgaard Madsen E, Nielsen P, Raun K (1988) Spiramycin: oral 
bioavailability and its tissue and bronchial secretions in calves. Proc IVth Congress 
of Eurolean Association for Veterinary Pharmacology and Toxicology. Budapest, 63 
Friton, G. HattumVan J.J.C. & Hörstermann D. (2003) Pharmacokinetics in plasma and milk 
of benzylpenicillin following repeated intramuscular administration of mamyzin 
(penethamate hydriodide) in lactating cows – Blackwell Publishing, Journal of 
Veterinary Pharmacology and Therapeutics. Proceedings of 9th Intenational Congress 
of the EAVPT, Lisbon, Portugal 26 (Suppl 1, august 2003) 100 – 101. ISSN: 0140-
7783ftp://ftp.fao.org/docrep/fao/007/y5468s/y5468s00.pdf 
Gentilini E., Denamiel G., Llorente P., Godaly S., Rebuelto M. & De Gregorio O. (2000). 
Antimicrobial susceptibility of Staphylococcus aureus isolated from bovine mastitis 
in Argentina. J. Dairy Sci. (June 2000) 83:1224-1227. ISSN 1525-3198 
Gianneechini, R.E., Concha, C. & Franklin, A. (2002) Antimicrobial susceptibility of udder 
pathogens isolated froma dairy herds in the West littoral region of Uruguay. Acta 
vet. Scand. (March 2002) 43 (1): 31-41. ISSN 1751-0147 
Gruet P, Maincent P, Berthelot X. & Kaltsatos V. (2001). Bovine mastitis and intramammary 
drug delivery: review and perspectives. Advanced drug delivery reviews, (Sep 2001); 
50: 245-259. ISSN 1872-8294. 
Hofshager M., Kruse H., Lassen J., Stavnes T-L., Essun K., Holstad G., Mork T., Schau J. & 
Grave K. (1999). Resistance in bacteria from infections in animals. In: Usage of 
antimicrobial agents in animlas and occurrence of antimicrobial resistance in bacteria from 
animals, feed, and food in Norway. NORM-VET, Ed. Hilde Kruse, ISSN-1502-4695, 
Oslo, Norway. 1999, pp 16-18. 
Hornish RE & Kotarski SF. (2002) Cephalosporins in veterinary medicine—Ceftiofur use in 
food animals. Current topics in medicinal chemistry, 2002;2: 717–731. [PubMed: 
12052187] ISSN 1873-4294 
  http://sedici.unlp.edu.ar/search/request.php?id_document=ARG-UNLP-TPG-
0000001053 
www.intechopen.com
 
Pharmacokinetic-Pharmacodynamic Considerations for Bovine Mastitis Treatment 
 
469 
Hunter P.A., G.N. Rolison & D.A. Witting. (1973). Comparative activity of amoxycillin and 
ampicillin in an experimental bacterial infection in mice. Antimicrobial agents and 
chemotherapy, Sep. 1973, 4(3), 285-293. ISSN 1098-6596 
Korhonen H, Kaartinen L. Changes in the composition of milk induced by mastitis. En: 
Sandholm M, Honkanen-Buzalski T, Kaartinen L, Pyörälä S, editors. The bovine 
udder and mastitis. 1 ed. Helsinki: Facultad de Medicina Veterinaria Universidad de 
Helsinki; 1995. p. 76-82. ISBN 9518340471 
Kuang, Y., Jia, H., Miyanaga, K., & Tanji, Y. (2009). Effect of milk on antibacterial activity of 
tetracycline against Escherichia coli and Staphylococcus aureus isolated from bovine 
mastitis. Applied Microbiology and Biotechnology, 84(1), 135-142. ISSN 1738-8872 
Labro M.T. (2000). Interference of antibacterial agents with phagocyte functions: 
immunomodulation or “immunofairy tales”. Clinical Microbiology Reviews, Vol. 13 
(4) (October 2000): 615-650, ISSN: 1098-6618 
Levison M.E. (2004). Pharmacodynamics of antimicrobial drugs. Infectious disease clinics of 
North America (Sep 2004) 18:451-465. ISSN 1557-9824. 
Lucas M.F. (2009b) Alternativas terapéuticas para el manejo racional de la mastitis subclínica 
por Staphylococcus aureus. June 2009. Thesis Dra. Nora Mestorino and Dr Jorge 
Errecalde.  
 http://www.fcv.unlp.edu.ar/index.php?option=com_content&view=article&id=6
65&Itemid=1299 
Lucas M.F; Moncada Cárdenas, A; Marchetti, L.; Lambertini, A.; Mestorino, N. & Errecalde, 
J. (2009a) Pharmacokinetics and T>MIC of amoxicillin-clavulanic acid in milk of 
lactating dairy cows with S. aureus subclinical mastitis. Proceeding BII-50. 
BIOCELL 2009, 33(1): A1-A52. ISSN 0327 – 9545. 
Lucas, M., Mestorino N., Errecalde J.O. (2009c) Pharmacokinetics and pk/pd integration of 
azithromycin in lactating dairy cows with subclinical mastitis caused by 
Staphylococcus aureus. Journal of Veterinary Pharmacology and Therapeutics, 33, 
132-140. ISSN: 0140-7783. http://dx.doi.org/10.1111/j.1365-2885.2009.01128.x 
Lucas, Mariana F. Nora Mestorino & Jorge O. Errecalde (2007) Macrólidos: novedades de un 
clásico grupo de antimicrobianos. Analecta Veterinaria 27 (1):36-45. ISSN 0365-5148    
Martinez M., Toutain P.L.& Walker R.D. (2006) The Pharmacokinetic-Pharmacodynamic 
(PK/PD) Relationship of Antimicrobial Agents. Antimicrobial Therapy in Veterinary 
Medicine, 4th ed. Giguère S, Prescott JF, Baggot JD, Walker RD, Dowling PM. 
Blackwell Publishing, Ames, Iowa, 2006. 626 pp. Chapter 5, pag 91. ISBN 0-8138-
0656-9. 
Mattie H, Zhang L, van Strijen E, Sekh BR, Douwes-Idema AEA. (1997). Pharmacokinetic 
and pharmacodynamic models of the antistaphylococcal effects of meropenem and 
cloxacillin in vitro and in experimental infection. Antimicrobial Agents and 
Chemotherapy (October 1997); 41(10): 2083-2088. ISSN 1098-6596  
Mercer H.D., Geleta J.N. & Carter G.G. (1974). Absorption and excretion of penicillin G from 
the mastitis bovine udder. Journal of the American Veterinary Medical Association, 
(Mar. 1974) 164. 613-617. ISSN 1943-569X 
Mestorino, N. (1993a). Thesis: Estudio Farmacocinético del Tianfenicol en Vacas Lecheras 
Holando Argentino. Universidad Nacional de La Plata.  
 http://sedici.unlp.edu.ar/search/request.php?id_document=ARG-UNLP-TPG-
0000001053 
Mestorino N., Alt M., Errecalde J. (1993b). The pharmacokinetics of thiamphenicol in 
lactating cows. Veterinary Research Communications, 17: 295-303. ISSN: 0165-7380 
www.intechopen.com
 
A Bird's-Eye View of Veterinary Medicine 
 
470 
Mestorino N., Speroni J. & Errecalde JO. (1995) Thiamphenicol concentrations in serum and 
milk after its intramammary administration to Holando Argentino cows. 
Proceedings II of The 3rd International Mastitis Seminar, ISBN 965-222-636, Tel 
Aviv, Israel, June 1995. 
Mestorino O.N, Turic E., Ive P.,  Errecalde J. (1997a) Concentraciones séricas y lácteas de 
oxitetraciclina luego de la administración de tres formulaciones por la vía 
intramuscular. VI Congreso Panamericano de la Leche. Buenos Aires. Argentina. 
Mestorino O.N, Turic E., Ive P., Errecalde J. (1997b). Concentraciones séricas y lácteas de 
amoxicilina luego de la administración de una formulación por la vía 
intramuscular. VI Congreso Panamericano de la Leche. Buenos Aires. Argentina. 
Mestorino, N.; Marchetti, M. L.; Turic, E.; Pesoa, J.; Errecalde J. (2009). Concentrations of 
danofloxacin 18% solution in plasma, milk and tissues after subcutaneous injection 
in dairy cows. Analytica Chimica Acta. Vol 637, 33-39. ISSN 0003-2670   
Moncada Cárdenas A, Marchetti L, Daniele M, Errecalde J, Mestorino N. Effect of pH on the 
antibacterial activity of azithromycin and penicillin against Staphylococcus aureus. 
BIOCELL, 33(1), 2009 
Mouton J.W., Dudley M.N., Cars O., Derendorf H. & Drusano G.L. (2005). Standardization 
of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective 
drugs: an update. Journal of antimicrobial Chemotherapy, 55, (March 2005), 601-607. 
ISSN 0305-7453 
Nickerson SC, Paape MJ, Harmon RJ. & Ziv G. (1986). Mammary leukocyte response to drug 
therapy. Journal of dairy science; (June 1986) 69 (6):1733-1742. ISSN 1525-3198 
Nickerson SC, Paape MJ. & Dublin AM. 1985. Effect of antibiotics and vehicles on bovine 
mammary polymorphonuclear leukocyte morphologic features, viability, and 
phagocytic activity in vitro. American journal of veterinary research; 46 (November 
1985):2259-2265. ISSN 1943-5681 
Nightingale C.H., Grant EM & Quintiliani R (2000). Pharmacodynamics and 
pharmacokinetics of levofloxacin. Chemotherapy 46 Suppl 1:6-14. ISSN1421-9794 
Nouws, J.F.M.; Guelen P, Mevius D. & Driessens F. (1986). Age difference in 
pharmacokinetics of an amoxycillin trihydrate-15% formulation administered 
intramuscularly to ruminants. The Vet. Quarterly. 8, 339-342. ISSN 0165-2176, 
OCLC: 5393794 
Ødegaard S, Sviland S. 2001 Comparison of intramammary antibiotic preparations for the 
treatment of clinical bovine mastitis caused by bacteria sensitive to penicillin. Proc. 
2nd Int. Symp. Mast Milk Quality, 2001:502-503. Vancouver, Canadá 
Oliver SP, Lewis TM, Lewis MJ, Dowlen HH, Maki JL. (1990). Persistence of antibiotics in 
bovine mammary secretions following intramammary infusion at cessation of 
milking. Preventive Veterinary Medicine 1990, 9:301-311. ISSN 1873-1716 
Otero, J.L.; Mestorino, O.N.; Errecalde, J.O. (2001a). Enrofloxacina: Una Fluorquinolona de 
uso exclusivo en veterinaria. Parte I: Química, Mecanismo de acción, Actividad 
Antimicrobiana y Resistencia Bacteriana. Analecta Veterinaria 21 (1): 31-41. ISSN: 
0365-5148 
Otero, J.L.; Mestorino, O.N.; Errecalde, J.O. (2001b). Enrofloxacina: Una Fluorquinolona de 
uso exclusivo en veterinaria. Parte II: Farmacocinética y Toxicidad. Analecta 
Veterinaria 21 (1): 42-49. ISSN: 0365-5148 
Owens W.E. & Watts J.L. (1987) Effects of Milk on Activity of Antimicrobics Against 
Staphylococcus aureus Isolated from Bovine Udders. J Dairy Sci. 70: 1946—1951. ISSN 
1525-3198 
www.intechopen.com
 
Pharmacokinetic-Pharmacodynamic Considerations for Bovine Mastitis Treatment 
 
471 
Owens W.E., Ray C.H., Watts J.L and Yancey R.J. (1997). Comparison of success of antibiotic 
therapy during lactation and results of antimicrobial susceptibility test for bovine 
mastitis. Journal of Dairy Science 80 (February 1997); 313-317. ISSN: 1525-3198 
Owens WE, Watts JL, Boddie RL. & Nickerson SC. (1988) Antibiotic treatment of mastitis: 
Comparison of intramammary and intramammary plus intramuscular therapies. 
Journal of Dairy Science. November 1988, 71, 3143-3147. ISSN 1525-3198 
Perner J, Winter P, Baumgartner W: Retrospektive Studie zum Einsatz von Synulox® in der 
Mastitistherapie (Retrospective study using Synulox® in mastitis therapy). 
Tierärztliche Praxis. 2002, 30, 286-294. ISSN:0303-6286 
Pol M, Ruegg PL. (2007). Relationship between antimicrobial drug usage and antimicrobial 
susceptibility of gram-positive mastitis pathogens.  Journal of Dairy Science.; 
90(1):262-73. ISSN 1525-3198 
Renard L, Sanders P, Laurentie M, Delmas JM (1996) Pharmacokinetic-pharmacodynamic 
model for spiramycin in staphylococcal mastitis. Journal of veterinary pharmacology 
and therapeutics (April 1996), 19 (2): 95-103. ISSN:0140-7783 
Rubin J.E., Ball K.R. & Chirino-Trejo, M. (2011). Antimicrobial susceptibility of 
Staphylococcus aureus and Staphylococcus pseudintermedius isolated froma 
various animals. The Canadian Veterinary Journal, (February 2011) 52:153-157. 
ISSN:0008-5286 
Russi N.B.; Bantar C. & L.F. Calvinho (2008). Antimicrobial susceptibility of Staphylococcus 
aureus causing bovine mastitis in Argentine dairy herds. Revista Argentina de 
Microbiología, (June 2008) 40 (2):116-119. ISSN: 0325-7541 
San Martín B., Kruze J., Morales MA., Leon B.; Esppinoza S.; Iraguen D., Puga J. & Borie C. 
(2002) Bacterial resistance of mastitis pathogens isolated from dairy cows in the Vth 
region, Metropolitan Region and Xth Region, Chile. Archivos de Medicina Veterinaria 
34(2): 1-12. ISSN0301-732X <http://www.scielo.cl/scielo.php? doi: 10.4067/S0301-
732X2002000200008. 
Sandholm M., Kaartinen L. & Pyörälä S. (1990). Bovine mastitis – why does antibiotic 
therapy not always work? An overview. Journal of Veterinary Pharmacology and 
Therapeutic. 13 (3) (September 1990), 248-260. ISSN 0140-7783 
Schifferli, D., Galeazzi, R.L., Nicolet, J. and Wanner, M. (1982) Pharmacokinetics of 
oxytetracylcine and therapeutic omplications in veal calves. Journal of veterinary 
pharmacology and therapeutics, December 1982, 5 :274-257. ISSN: 0140-7783 
Shem-Tov, M., Rav-Hon, O., Ziv, G., Lavi, E., Glickman, A. and Saran, A., 1998. 
Pharmacokinetics and penetration of danofloxacin from the blood into the milk of 
cows. Journal of veterinary pharmacology and therapeutics, 21:209-213. ISSN: 0140-7783 
Shojaee Aliabadi F. & P. Lees (2003) Pharmacokinetic–pharmacodynamic integration of 
danofloxacin in the calf. Research in Veterinary Science, Volume 74, Issue 3, June 
2003, Pages 247-259. ISSN 1532-2661  
Sol J, Sampimon OC, Barkema HW & Schukken YH (2000) Factors associated with cure after 
therapy of clinical mastitis caused by Staphylococcus aureus. Journal of dairy science. 
(February 2000), 83, 278-284. ISSN 1525-3198 
Sompolinsky D., Gluskin I. & Ziv G. (1969). Pantothenate-requiring dwarf colony variants of 
Staphylococcus aureus as the etiological agent in bovine mastitis. J. Hyg. (Camb.) 
Sep; 67(3):511-6. ISSN: 0022-1724 
Taponen S., Jantunen A., Pyoral E. & S. Pyörälä. (2003). Efficacy of targeted 5-day combined 
parenteral and intramammary treatment of clinical mastitis caused by penicillin-
www.intechopen.com
 
A Bird's-Eye View of Veterinary Medicine 
 
472 
susceptible or penicillin-resistant Staphylococcus aureus. Acta veterinaria 
Scandinavica; 44(1-2):p.53-62. ISSN 1751-0147 
Thornsberry, C., and J. C. Sherris. 1985. Laboratory tests in chemotherapy, general 
considerations. Page 959 in Manual of clinical microbiology. 4th ed. E. H. Lennette, ed. 
Am. Soc. Microbiol., Washington, DC. 
Toutain P.L. (2002). Pharmacokinetic/pharmacodynamic integration in drug development 
and dosage-regimen optimization for veterinary medicine. AAPS Pharma Sci 4(4) 
December 2002:160-188. ISSN: 1522-1059 
Turic E, N Mestorino, J Pesoa, M Colantonio, J.O. Errecalde (2003a). Azithromycin Serum 
and Mammary Secretion Concentrations after its Intramammary Administration in 
Healthy and Mastitic Cows at Drying off. Journal of Veterinary Pharmacology and 
Therapeutics. Volume 26, supplement 1, 131. ISSN:0140-7783 
Turic E, N Mestorino, J Pesoa, M Colantonio, J.O. Errecalde (2003b). Azythromicin Serum 
and Milk Concentrations After Intramuscular Administration In Healthy And 
Mastitic Milk Cows. Journal of Veterinary Pharmacology and Therapeutics. Volume 26, 
supplement 1, 130. ISSN:0140-7783 
Turic, E.; Mestorino, N.; Errecalde, J.O. (2006) Farmacocinética intramuscular de 
azitromicina en vacas lecheras, impacto en salud pública. Sociedad Argentina de 
Farmacología y Terapéutica, Asociación Médica Argentina. Nº37 vol 4: 17-20. www.ama-
med.org.ar 
Van Bambeke F., M. Barcia-Macay, S.Lemaire & P.M. Tulkens. (2006). Cellular 
pharmacodynamics and pharmacokinetics of antibiotics: Current views and 
perspectives. Current Opinion in Drug Discovery & Development, (Mar 2006) 9(2):218-
230. ISSN 2040-3437 
Wilson, D.; Spensley, M.S.; Baggot, J.D. & Hietala, Sh.K. (1988). Pharmacokinetics and 
estimated bioavailability of amoxycillin in mares after intravenous, intramuscular, 
and oral administration. Am.J.Vet.Res. (October 1988) 49 (10) 1688-1694. ISSN: 
0002-9645.  
Wright D.W.  Brown G.H.,  Peterson M.L. &  Rotschafer J.C. (2000). Application of 
flouoroquinolone pharmacodynamics. Journal of Antimicrobial Chemotherapy 46 (July 
20, 2000):669-683, ISSN 1460-2091 
Zelenitsky S.A. Ariano R.E., Iacovides H., Sun S. & Harding G.K.M. (2003) AUC0-t/MIC is a 
continuous index of fluoroquinolone exposure and predictive antibacterial 
response for Streptococcus pneumonia in an in vitro infection model. Journal of 
Antimicrobial Chemotherapy 51 (March 2003):905-911. ISSN 1460-2091 
Ziv G. & Sompolinsky D. (1976) Studies on the pathogenicity of thiamineless dwarf-colony 
variants of Staphylococcus aureus isolated from the bovine udder. Res. Vet. Sci.20 
(3) (May 1976), 288-294. ISSN: 0034-5288 
Ziv G. (1980a) Drug selection and use in mastitis: systemic vs. local therapy. Journal of the 
American Veterinary Medical Association (May 1980); 176:1109-1115. ISSN: 0003-1488  
Ziv G. (1980b) Practical pharmacokinetic aspects of mastitis therapy: Parenteral treatment. 
Veterinary medicine, Small Animal Clinician  (Feb.1980); 75:277-290. ISSN: 0042-4889 
Ziv G. (1980c). Practical pharmacokinetic aspects of mastitis therapy: Intramammary 
treatment. Veterinary medicine, small animal clinician (April 1980); 75:657-670. ISSN: 
0042-4889 
Ziv, G. & Nouws, J.F.M. (1979). Serum and milk concentrations of ampicillin and 
amoxycillin in ruminants. Refuah Veterinarith 36: 104-110. ISSN 0034-3153 0034-3153 
www.intechopen.com
A Bird's-Eye View of Veterinary Medicine
Edited by Dr. Carlos C. Perez-Marin
ISBN 978-953-51-0031-7
Hard cover, 626 pages
Publisher InTech
Published online 22, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Veterinary medicine is advancing at a very rapid pace, particularly given the breadth of the discipline. This
book examines new developments covering a wide range of issues from health and welfare in livestock, pets,
and wild animals to public health supervision and biomedical research. As well as containing reviews offering
fresh insight into specific issues, this book includes a selection of scientific articles which help to chart the
advance of this science. The book is divided into several sections. The opening chapters cover the veterinary
profession and veterinary science in general, while later chapters look at specific aspects of applied veterinary
medicine in pets and in livestock. Finally, research papers are grouped by specialisms with a view to exploring
progress in areas such as organ transplantation, therapeutic use of natural substances, and the use of new
diagnostic techniques for disease control. This book was produced during World Veterinary Year 2011, which
marked the 250th anniversary of the veterinary profession. It provides a fittingly concise and enjoyable
overview of the whole science of veterinary medicine.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Nora Mestorino and Jorge O. Errecalde (2012). Pharmacokinetic – Pharmacodynamic Considerations for
Bovine Mastitis Treatment, A Bird's-Eye View of Veterinary Medicine, Dr. Carlos C. Perez-Marin (Ed.), ISBN:
978-953-51-0031-7, InTech, Available from: http://www.intechopen.com/books/a-bird-s-eye-view-of-veterinary-
medicine/pharmacokinetic-pharmacodynamic-considerations-for-bovine-mastitis-treatment
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
